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Foreword
Human resources for health are at a critical low. The World Health Organization estimates that the current shortage of health 
workers is in excess of 7.2 million worldwide and that, by 2035, the shortage will reach 12.9 million. Pharmacists, in particular, 
are lacking in the workforce in many countries. In addition, education and training needs to be strengthened globally.
Pharmacy needs a global vision that encompasses the sharing of experiences, gathering of evidence and collaborative guidance 
to facilitate country-level initiatives.
FIPEd is the name given to the component group of the International Pharmaceutical Federation (FIP) that is bringing together 
all of the federation’s efforts in transforming and strengthening professional pharmacy and pharmaceutical sciences education 
globally. It is organised as a cross-cutting initiative that includes both of the boards of FIP as well as its governance bodies.  
More than 100 practitioner and scientific educators and over 130 deans of schools of pharmacy from throughout the world 
are involved in congress programming on educational issues. 
The FIPEd team prepares technical and policy papers on key areas of education, contributes to an online international journal on 
pharmacy education, gathers leaders in education to establish a future agenda for transformation of pharmaceutical education, 
and links educational policy issues to national needs for workforce development, capacity building and quality assurance.
All of these initiatives are closely tied to enhancing appropriate medicines use in global health systems, with a strong emphasis 
on competency development across the continuum of the pharmaceutical workforce for practice and science. 
Education and workforce development are the foundations for advancement in both pharmacy practice and the pharmaceutical 
sciences, and the strengthening of educational programmes in the global community of universities and training centres are 
integral parts of FIP’s Vision for 2020. This report additionally links to two other FIP reports published in 2015: ‘Global Pharmacy 
Workforce Intelligence: Trends Report’ and ‘Interprofessional Education’. FIP stakeholders have identified all these topics as 
being globally important and valuable for professional leadership bodies worldwide. Expansion of pharmacists’ roles and scopes 
of practice to assure safe, effective and efficient medication use is strongly reliant on educational programmes that are socially 
accountable and meet international standards for quality. In that vein, FIPEd has partnered with the World Health Organization, 
the United Nations Agency for Education and Social Development (UNESCO) as well as several leading universities and national 
organisations.
FIPEd’s Global Report on Advanced Practice and Specialisation in Pharmacy is the first publication of its kind to provide 
a baseline on the current growing global trend to formally recognise the advancement of practice, which includes elements 
of specialisation and professional recognition. We share this knowledge from our members to our members and beyond, 
to trigger dialogue and action towards stronger policies. We hope that this will stimulate collaborations/partnerships 
between all stakeholders, including professional organisations and universities taking up the important role of advocating 
transformation of professional development education at the national level.  
This report, and others like them, are only possible due to the commitment and expertise provided by the principal authors and 
the personnel who have contributed to case studies and the provision of evidence and data. This report represents a significant 
commitment of time and effort, and on behalf of the FIPEd, I am sincerely grateful to the individuals, organisations and 
institutions who have made these significant contributions. Without their contribution and commitment, these influential and 
helpful publications would not be possible.
William N. Charman, BPharm, PhD
FIP Education Initiative (FIPEd) Steering Committee Chair
Sir John Monash Distinguished Professor
Dean, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University
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The data retrieved from case studies also makes clear that 
recognised “advancement” and “specialisation” (independent 
of how countries may define these terms locally) must be 
linked with a modern understanding of competence and 
capability of performance. Consequently, professional 
recognition of practitioner advancement must be clearly 
identified as including both education and practice 
development components.
There is a close association in those countries with formal 
recognition processes in place (for specialisation and 
advancement) and acknowledgement of tangible benefits for 
workforce access to specialisation and advancement. These 
benefits included enhanced career pathways, enhanced 
remuneration for practitioners and enhanced individual 
esteem and prestige.
The global trend is for pharmacy to continue to become 
a more clinical, patient-facing profession, with enhanced 
responsibilities and accountabilities for pharmaceutical care 
in clinical environments; hence, clear pathways for workforce 
development, coupled with professional recognition and 
credentialing of practitioners, becomes an important 
consideration. There is a clear opportunity for transnational 
collaboration and further opportunities for transnational 
recognition of advanced capabilities for the pharmacy 
workforce.
The public and our patients expect the highest possible 
pharmaceutical care from professional practitioners 
worldwide, without exception. A clear demonstration of 
competence and capability that is commensurate with 
advanced and expert practice is a strong message to policy 
makers and civil society that pharmacists possess this 
expertise. Professional recognition, credentialing and quality 
assured specialisation are part of the demonstration of 
competence and capability. 
It is in the interest of patients, health systems and our 
profession that a common and shared understanding of 
what we mean by “specialisation” and by “advanced practice” 
is developed. This is a key driver for future workforce 
development and this report can be seen as a starting point for 
this global discussion.
FIP Education Initiative surveyed 48 countries and territories 
worldwide to obtain information concerning specialisation 
and advanced practice policy and implementation at country 
level. Both terms were described within the context of the 
survey in order to assist with responses. Specialisation 
was taken to mean advanced with narrow scope; advanced 
practice was taken to mean overt advanced (beyond 
foundation) with broad scope of practice. The survey obtained 
48 country and territory level responses ranging across WHO 
regions, economic and demographic characteristics.
In addition, a series of case studies (17 countries) illustrates 
trends in policy development related to specialisation and 
advancement. From these, and the initial quantitative survey, 
a preliminary series of definitions and a glossary has been 
formulated in order to seed global debate about advancement 
of practice and professional understanding across borders. 
This report is the most comprehensive collection of data and 
evidence that relates to practitioner advancement of practice 
and policy, and maps out a wide range of national initiatives 
worldwide. This report should be viewed as a first attempt to 
map out global trends and will stimulate further reportage and 
analysis as engagement in this practice continues to progress. 
In our sample around half of the respondents (23, 48%) 
indicated the existence of an agreed national level definition 
of “specialisation” although there is variance between these 
definitions.  “Advanced practice” as an agreed country level 
definition was indicated by fewer countries (11, 23%) with a 
smaller number of nine countries (19%) indicating country 
level consensus on both specialisation and advanced practice. 
Advanced practice in this context was taken to mean a broad 
scope of practice, beyond foundation level. 
There are no clear associations with the existence of country 
level definitions of specialisation or advanced practice with 
national pharmacist capacity; high-capacity countries do 
not have a tendency to have definitions compared with low 
capacity countries. However there is a level of association with 
economic development; higher income countries tend to have 
a provision of formalised specialisation and advanced practice 
contrasted with lower-income countries.
For workforce development of advanced and specialised 
practice a number of countries stated categorically that 
practitioner frameworks were currently available — or under 
active development — and accounted for 58% (28 nations) 
in this sample. It was notable that 10 countries indicated 
that frameworks had been adapted from the work of other 
countries showing potential collaborative practice between 
countries and leadership organisations. It is clear to us that 
the use of national developmental frameworks, ideally linked 
with the concept of “professional curricula”, is a key workforce 
development activity in order to progress professional role 
enhancement and pharmaceutical service delivery.
PART 1
KEY MESSAGES
William N. Charman, BPharm, PhD
FIP Education Initiative (FIPEd) Steering Committee Chair
Sir John Monash Distinguished Professor
Dean, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University
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Current entry-level pharmacists practice within a broad scope 
and at a general foundation performance level. 
As the profession of pharmacy continues to expand to 
include more complex roles and responsibilities, entry 
level performance associated with skills, knowledge, and 
behaviours does need to be shown 
to meet defined foundation competency expectations 
to provide public and patient trust and assurance.6
Internationally, a number of countries have developed 
and implemented frameworks to describe foundation 
competencies for pharmacy practice. One of the first countries 
using developmental frameworks was the United Kingdom, 
through the Competency Development and Evaluation Group 
(CoDEG), that developed the General Level Framework (GLF) - 
a Framework for Pharmacist Development in General 
Pharmacy Practice.
Based on this work and others, FIP developed the Global 
Competency Framework (GbCF) v1. The GbCF v1 is an 
example of a developmental framework, which can support 
countries to adapt and develop their own. It contains a core 
set of behavioural competencies synthesised from several 
documents that are generally applicable for the pharmacy 
workforce globally. It acts as a mapping tool for the creation 
of country specific needs for the development of practice 
and practitioner professional development. In synergy with 
assessment tools, countries can implement the GbCF into 
practice, developing education and training infrastructures 
for their practitioners.4,7
In 2010 collaboration between CoDEG, Monash University and 
the Society of Hospital Pharmacists Australia resulted in the 
development of the clinCAT (Clinical Competency Assessment 
Tool), which has been implemented nationally for peer review 
of professional practice.8 Recently the GLF has been adopted 
and revised by the Royal Pharmaceutical Society (RPS) as 
the “Foundation Pharmacy Framework”. This underpins the 
RPS’s new Foundation Programme that supports pharmacists 
to deliver safe and effective pharmaceutical care, for both 
early careers and for ‘return to practice’ or career break 
practitioners.7 
There are a variety of other initiatives developed globally to 
encourage and recognise advancing practice and there exists 
an opportunity to develop a validated global competency 
assessment tool to support more advanced practice. 
Advancing practice
The knowledge and skills that pharmacists acquire through 
foundation practice provide the platform for advancing 
practice. An evaluation of competency development 
frameworks in pharmacy education has recommended 
developing a formal structure to offer support of post-
registration pharmacists through mentoring and supervision.9 
Authors
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Lead for Advanced Practice and Director of the Postgraduate 
Studies and Professional Development Unit, Faculty of 
Pharmacy and Pharmaceutical Sciences, Monash University, 
Australia, kirstie.galbraith@monash.edu; Andreia Bruno, FIPEd 
Project Coordinator and Researcher, education@fip.org; Ian 
Bates, Director of the FIP Education Development Team, FIP 
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Pharmacists are expected to have the professional expertise 
to effectively manage complex patient cases and complex 
combinations of medicines. The concept of medication 
therapy management (MTM)1 and similar services continue 
to be introduced and developed within healthcare systems 
across the world, and there is strong evidence demonstrating 
improved health and system outcomes as a result of 
pharmacists providing MTM-type services.2 As current health 
systems and patient care continue to evolve in complexity and 
challenge, there is more demand for pharmacists to provide 
complex services and to take on roles which are extended, 
specialised and more advanced than current entry level scope 
of practice. In order to ultimately provide these services, 
pharmacists would benefit from having clear developmental 
pathways from foundation practice to practice, which is more 
advanced, and to have opportunity to be formally recognised 
as advanced practitioners.
Foundation practice
In a report prepared for the Royal Pharmaceutical Society (GB) 
“Professional Recognition and Professional Advancement”, by 
the Joint Partners Credentialing Task Group, it was identified 
that healthcare professionals’ ability to enhance therapeutic 
outcomes, patients’ quality of life, scientific advancements 
and public health imperatives, depends upon a sound 
foundation of competence and capability that should be 
acquired during initial education and experiential training.3  
Competency refers to the combination of skills, knowledge, 
behaviours, and attitudes that an individual develops 
through education, training, and experience.4 These 
behavioural competencies can be used to develop an 
individual’s performance and are a necessary prerequisite 
for a practitioner to move forward in advanced practice or 
specialisation.5 It is necessary for pharmacists globally to 
demonstrate an appropriate foundation practice before 
obtaining the capabilities required to be considered 
competently specialised, or advanced in their practice. 
It is crucial for professional leadership bodies to support 
pharmacists, in various stages of their career progression, 
through use of developmental frameworks.4 
PART 2
INTRODUCTION
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Recent experience in Australia has identified the importance 
of recognising capable pharmacy practitioners.10 Some areas 
of the Australian pharmacy workforce have begun 
to recognise advanced practitioners and there is currently 
a pilot program underway to formally credential advanced 
practice pharmacists.11 There is recognition that the ability 
of an advanced pharmacy practitioner to make clinical 
decisions and deliver patient care is at a significantly higher 
level than the abilities of an entry-level pharmacist.10 This 
observation supports the need for recognition of more 
advanced practice and for competency frameworks to develop 
capable pharmacy practitioners, possessing a competence 
level beyond that of entry-level pharmacists, to deliver the 
best possible patient care. 
Similar work has been underway in Great Britain for a number 
of years and has culminated recently in the establishment of 
the Royal Pharmaceutical Society Faculty, a service aiming at 
recognising and validating advanced practice. Membership of 
the Faculty is a quality assurance marker that a practitioner 
is more advanced, a confirmation that they can handle 
complexity and make complex decisions with confidence.12
Requirements for more advanced practice
A key requirement for advancing practice in the profession will 
be to provide a sufficiently robust definition and description of 
“advancement” that will resonate with professional leadership 
bodies and service providers globally. 
One model adopted by Australia (Advanced Pharmacy 
Practice Framework - APPF)13 and the GB (Advanced Pharmacy 
Framework - APF)14 aims to support pharmacists to determine 
their current competency levels, and the skills, knowledge, 
behaviours, and values that need to be developed to move 
forward on the continuum of advanced pharmacy practice. 
Both frameworks have identified similar key competency 
clusters that are considered necessary for development of 
advanced stages of practice. While the terminology differs 
slightly between the two frameworks, there is clear resonance 
with the identified domains or clusters, which can be 
represented by the APF as follows12:
                  1.       Expert professional practice
                  2.       Collaborative working relationships
                  3.       Leadership
                  4.       Management
                  5.       Education, training, and development,
                  6.       Research and evaluation
These domains of advanced competency tend to recur in 
other professions and have an evidence base to support their 
relevance and credibility.14 
Other jurisdictions have taken a slightly different approach 
to describing and recognising advanced practice. Rather than 
using a competency framework some have requirements 
including a combination of certification by dedicated 
structures (i.e. Board of Pharmaceutical Specialties in the USA), 
specific continuing education, a specified number of years 
in practice, and designated postgraduate courses of study. 
This report attempts to describe the current global practices 
supporting development and recognition of advanced practice.
Benefits of more advanced practice
There are benefits from developing and recognising 
advancement in pharmacy practice. Pharmacists working 
at a recognised level of advancement, with a higher set of 
competencies, improve and safeguard patient safety and 
more effectively manage complexity in many areas of expert 
practice. Professional recognition of advanced practice 
improves acceptance by other colleagues in the clinical team, 
but also in other areas of practice such as research, education 
and management.  It also provides role models and a source 
of mentorship for novice and less experienced pharmacists, 
including pre-service or pre-licensed pharmacists. Recognising 
pharmacists as advanced practitioners enables employers 
and senior managers to have evidence of capability.13 Overall, 
the movement towards recognising advanced practice in 
pharmacy represents progression of the pharmacy workforce.
Challenges and barriers
There are challenges and barriers to the development and 
recognition of more advanced pharmacy practice. Global 
recognition of advanced pharmacy practice is not yet optimal, 
and there is lack of agreement regarding what constitutes 
advanced practice. Barriers to consider include differences 
in the structure of healthcare systems, pharmacist initial 
education, and variances in scope of practice.6 In countries 
where pharmacists can be recognised as “advanced 
practitioners”, collaborative practices between pharmacists 
and physicians, for example, are often already well established 
and pharmacists tend to provide pharmaceutical and clinical 
services directly to patients. 
One of the greatest challenges in encouraging pharmacists 
to seek recognition of more advanced pharmacy practice is 
that pharmacists may not receive adequate compensation/
reimbursement for their services. For example, in California, 
USA, the designation advanced practice pharmacy (APP) was 
created to recognise the expansion of a pharmacist’s scope 
of practice through Collaborative Practice Agreements (CPA). 
Even with the APP designation and growing establishment 
of CPA between pharmacists and physicians, there is no 
law in California that authorises pharmacists to receive 
reimbursement.2 This shows that even in places where 
advanced practice pharmacy is growing and being recognised, 
there are still barriers to overcome. There is starting to be some 
evidence that this issue is slowly being addressed. 
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Specialisation
In some jurisdictions advancement and specialisation are 
used almost synonymously and this can result in confusion 
regarding the use of these terms. There have been attempts 
to clearly define these two concepts.11,15 In Australia the term 
“specialist” is protected under national law and can only be 
used by designated healthcare practitioners. As pharmacists 
are not included in this group more generic terms such as “area 
of focus”, “area of expert practice” or “defined area of practice” 
are used, further complicating global understanding in this 
area. 
The ‘PHARMINE’ (Pharmacy Education in Europe) report 
Identifying and Defining Competencies: A clear map for 
scientific and professional competencies as applied to 
hospital pharmacy outlined a European context for 
specialisation and delivered a consensus derived set 
of competencies required for specialisation within pharmacy 
practice. The aim of this European consensus was to develop 
a core set of competencies for specialisation that are 
applicable across sectors of advanced levels of practice. 
The report stated that specialisation is taken to mean, 
“becoming an expert in one particular skill or area” but 
also stated that there is no universal consensus on what 
“specialisation” denotes.16 It can be argued that specialisation 
denotes a specific sector of practice such as hospital pharmacy 
or community pharmacy and is a “horizontal” differentiation 
from other practitioners (describing scope of practice), while 
advancement is a “vertical” differentiation (referring to 
level of performance).15,17 It can also be argued that within 
each practice sector exist narrower fields of specialisation, 
for example “oncology pharmacy” or “drug information 
pharmacist”. 
Figure 1: Advanced and specialist - broad and narrow scope.
However, it is commonly recognised that specialisation is seen 
in more advanced areas of practice and should not be focused 
principally on job description or functional task list, but rather 
a certain (defined) level of competence within a sector of 
practice. Figure 1 depicts this generalised concept.
The PHARMINE report outlines a competency-based approach 
to specialisation and focuses on a “set of learned behaviours 
which possess the following attributes: not dependent on 
job descriptions or functional task lists; generalisable, and 
hence transferable across jobs and expected tasks; and 
educational and developmental in nature… hence can be 
applied to practitioner development across sectors and scope 
of practice”. A Specialist and Advanced Level Framework for 
Hospital Practice was developed in collaboration with the 
European partners and contains two components: 
“core clusters” and “specialisation competency clusters”. 
The “core clusters” represent competencies, which are 
common to all sectors of pharmacy practice and include:
 
                  1.       Leadership
                  2.       Management
                  3.       Education, training, and development   
                  4.       Innovation and evaluation [analogous 
         to ‘research and evaluation’]
and a set of related competencies for each area, with three 
levels of performance demonstrating advancement. This is 
consistent with the idea that many advanced competencies 
are generic regardless of sector, or area of expertise.   
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The core framework is intended to be used as a tool to 
progress, within a specific area of practice, toward a level of 
mastery in each of the four areas or domains. This approach 
shows a consistency in the identification and characterisation 
of domains that relate to “advanced practice”.17
Professional recognition, 
credentialing and privileging
In a wider context, Australia, Europe, and North America have 
taken a special interest in the credentialing of healthcare 
professionals. Within this context, credentialing is used as 
an umbrella term to encompass processes to ensure that 
individuals and/or organisations have complied with accepted 
standards, therefore acting as an evaluation of a professional’s 
training, experience, and competence. In North America, the 
term “board certification” is equivalent to credentialing. 
There is evidence supporting the notion that “credentialed” 
healthcare practitioners, including pharmacists, tend to be 
associated with provision of a higher quality of patient care 
(including complex care), improved clinical outcomes, and an 
increase in patient safety as compared to non-credentialed 
or non-board-certified practitioners.18
In the USA, the Council on Credentialing in Pharmacy says 
that the current set of credentials required assures that an 
entry-level pharmacist is qualified to provide a standard level 
of care. These credentials include earning “an accredited 
professional pharmacy degree and a license awarded 
upon successful completion of a national postgraduate 
examination administered by the National Association of 
Boards of Pharmacy on behalf of state boards of pharmacy”.15 
Although this is a standard process, the continuously growing 
healthcare system requires pharmacists to provide skills that 
are beyond entry-level. 
The Board of Pharmacy Specialities (BPS), in USA, has been 
credentialing pharmacists in special areas of practice since 
1976. BPS has promoted and recognised the value of specialty 
pharmacy training as well as the knowledge and skills required 
to obtain a specialty board certification. This initiative ensures 
improved patient care and optimal medication outcomes.19 
Recognition of specialty practice in other countries is 
extremely variable, both in the pathways followed and the 
responsible organisation. 
In 2010, following new legislation in the UK, professional 
regulation and professional leadership were separated and the 
re-formed RPS in Great Britain was able to commence activities 
associated with professional recognition and credentialing, 
along lines similar with the medical ‘Royal Colleges’. The 
subsequent Joint Partners Credentialing Task Group report 
determined the role of the professional leadership body in 
creating a professional recognition based on peer assessment 
and developmental frameworks. 
RPS peer review panels have now been established for the 
purpose of professional recognition and credentialing, and to 
enable advanced support for practitioners.3 Access to a formal 
framework such as this allows pharmacists to evaluate their 
own performance against a framework and to determine the 
support required for continued development as evaluated by 
peers.10
Continuing professional development
As pharmacy practice continues to progress, so do the 
requirements for continuing education (CE). Continuing 
education is evolving into more complex, competency-based 
education, which incorporates application of knowledge and 
demonstration of skills. The term “continuing education” is 
transforming into “continuing professional development” 
(CPD). CPD is essential in order to maintain modern pharmacy 
practice in a healthcare system that continually advances.20
Summary 
In order to utilise pharmacists to their full potential as 
advanced practitioners, the development and global 
acceptance of standardised competencies, which pharmacists 
are required to meet, is essential. A competent pharmacist will 
be able to provide the highest quality of healthcare to their 
patients, with a lower rate of medication errors, leading to 
increased health outcomes and patient satisfaction. 
Additionally, a pharmacist who possesses the qualities 
of competence and capability will allow other healthcare 
professionals to recognise the expertise of advanced practice 
pharmacists. Several frameworks have been developed at 
national level and internationally such as the FIP GbCF. The 
development of competency frameworks will be useful for the 
inevitable progression of the profession of pharmacy toward 
advanced practice.4,5
Pharmacists continue to improve their expertise and value to 
the healthcare workforce. Before improved competence and 
recognition of advanced pharmacy practice can be achieved, 
more standard competency requirements must be established. 
There are still several barriers to overcome before pharmacists 
can be recognised as advanced practitioners, but overall 
the benefits of creating a competency system for advanced 
practice outweighs the challenges that may be faced along 
the way. 
10
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Key messages
• FIP Education Initiative surveyed 48 countries and territories 
worldwide to obtain information concerning specialisation 
and advanced practice policy and implementation at country 
level. Both terms were described within the context of the 
survey in order to assist with responses. Specialisation 
was taken to mean advanced with narrow scope; advanced 
practice was taken to mean overt advanced (beyond 
foundation) with broad scope of practice. The survey obtained 
48 country level responses ranging across WHO regions, 
economic and demographic characteristics.
• In this sample around half of the respondents (23, 48%) 
indicated the existence of an agreed country level definition 
of “specialisation”. “Advanced practice” as an agreed national 
level definition was indicated by fewer respondents (11, 23%) 
with a smaller number of nine countries (19%) indicating 
country level consensus on both specialisation and advanced 
practice. Advanced practice in this context was taken to mean 
a broad scope of practice, beyond foundation level.
• There are no clear associations with the existence of country 
level definitions of specialisation or advance practice with 
national pharmacist capacity; high capacity countries do 
not have a tendency to have definitions compared with low 
capacity countries. However there is a level of association with 
economic development; higher income countries tend to have 
a provision of formalised specialisation and advanced practice 
contrasted with lower income countries.
• For workforce development of advanced and specialised 
practice a number of countries stated categorically that 
practitioner frameworks were currently available – or under 
active development – and accounted for 58% (28 nations) 
in this sample. It was notable that 10 countries indicated 
that frameworks had been adapted from the work of other 
countries potentially showing a high degree of collaborative 
practice between countries and leadership organisations.
PART 3   
ADVANCED PRACTICE AND 
SPECIALISATION DESCRIPTION
• Twenty countries (42% of the sample) indicated that 
formal post-nominal titles for individuals were available for 
professional recognition of advancement or specialist practice. 
Examples are provided. Professional organisations, rather 
than statutory regulators, seemed to be predominant in the 
recognition and awarding of specialist post-nominal titles.
• Prescribing as a specialisation was present in 19% of the 
sample (9 countries).
• There is a close association in those countries with formal 
recognition processes in place (for specialisation and 
advancement) and acknowledgement of tangible benefits for 
workforce access to specialisation and advancement. These 
benefits included enhanced career pathways, enhanced 
remuneration for practitioners and enhanced individual 
esteem and prestige.
3.1 Introduction and methods
There is a growing global trend to formally recognise 
the advancement of practice, which includes elements 
of specialisation and professional recognition. There 
is evidence presented in this report suggesting there 
are benefits in developing a clear definition for scope 
of practice, for advanced practice and specialisation, 
and that these benefits support workforce development 
and progressive service delivery of pharmaceutical care.
This section of the report presents a summary of the survey 
administered to membership organisations or countries 
that are represented by FIP. The survey was developed in 
collaboration with the FIP Collaborating Centre, University 
College London School of Pharmacy, Faculty of Pharmacy 
and Pharmaceutical Sciences at Monash University, and FIP 
Education Initiative. The survey was validated by an expert 
working group, drawn from a cross-section of FIP sections 
and special-interest groups.
The 2015 advanced practice and specialisation survey was 
conducted between January 2015 and May 2015. FIP member 
organisations, country and territory level contacts from 
regulatory, professional and government agencies and 
universities were approached for responses to a survey, 
asking for quantitative and multiple-choice responses 
concerned with advanced practice and specialisation in their 
country. Demographic and economic data was also collected.
The survey tool was made available in 2 languages (English 
and Spanish). The dataset was cleaned and checked with 
respondents before being prepared for analysis. The survey 
tool, data tables and the report are available for download 
from www.fip.org/educationreports. 
Frequency counts and valid percents (taking into account 
missing data for some items) are reported here.
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.3.2 Terminology, nomenclature 
and language 
The survey reported here was necessarily administered 
to member organisations before the full report data set had 
been retrieved and analysed. Hence, the survey terminology 
and language was given careful consideration beforehand, 
and use of expert opinion and consensus from FIP sections 
was sought. The terminology used for responding to the 
survey item set used “specialisation” and “advanced practice” 
as labels and a definition of contextual meaning was provided 
within the survey.
“Specialisation” was taken to relate to a higher, but narrow, 
focus on scope of practice.
“Advanced practice” was intended to relate to a higher, 
but broad, scope of practice. 
Both terms, de facto, relate to practice that is beyond 
initial education and training, and beyond what can 
be broadly considered as foundation practice or training, 
and both cases, generally relate to practice beyond three 
years post-registration/licensing. See Figure 1 for a schematic 
of this concept.
For the interpretation of the survey data, this was the context 
for organisations to provide responses.
Figure 1: Advanced and specialist - broad and narrow scope.
3.3. Survey summary 
and sample demographics
In total, FIP Education Initiative was able to obtain broad data 
from 48 countries and territories worldwide. The data were 
subject to quality assurance and checking processes, before 
being coded and entered into a database for subsequent 
analysis. Analysis was conducted primarily by descriptive 
statistics. The analysis presented here should be interpreted 
within the limitations of generalisation and based on the best 
available data collected by the FIPEd team. It is clear from an 
overview of the detail provided by respondent countries that 
codifying and defining advanced practice and specialisation
is complex. Nonetheless this section of the report will provide 
a first view of the global situation for advancement of 
pharmacy practice. Table 1 shows responses by WHO region of 
origin.
Table 1: Respondent frequencies by WHO region.
By comparing with the proportions of WHO member states 
within regions it can be seen that the survey returns are 
weighted more towards European countries and less on 
African countries. For the other WHO regions there are similar 
sample proportions.
 
The respondent countries were also classified by income 
level using the current World Bank categorisation and this 
information is shown in Table 2 for interest and context.
Table 2: Responses by World Bank income classification.
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In this sample, there are higher proportions of responses from 
upper and higher income countries, the largest proportional 
responses from European countries, which may contribute to 
this weighting. In addition, Table 3 shows the organisations 
responding to the survey in this sample (noting that some 
responses, especially those with university affiliations, 
were responding on behalf of membership and leadership 
organisations).
Table 3: Responding organisations and affiliations.
Figure 2: Pharmacist capacity standardised as per 10,000 population 
(n=48 countries who responded to this survey). 
The sample of 48 countries and territories in this report has 
an equitable distribution between high and low capacity 
countries, as seen in Figure 2. The sample mean capacity 
statistic for the 48 countries and territories represented is 
8.4 pharmacists/10,000 population, which is larger than a 
global mean published by FIP Education Initiative in its 2012 
Workforce Report (a mean of 6.02 pharmacists/10,000 with 
a sample size of n = 109 countries) and is a consequence of 
sample size difference (www.fip.org/education). We would 
conclude that we have relatively fewer lower capacity 
countries represented in this survey. Nonetheless, the 
survey represents a range of capacities and economies for 
generalisability of the analysis.
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3.4 Specialisation and advanced practice
In the survey, respondent organisations were asked if 
there was a clear separation of regulation (licensing) from 
professional leadership (membership organisation) at country 
level. Thirty-eight (38) countries and territories indicated that 
there is separation of responsibilities, with 10 countries and 
territories (20.8%) indicating non-separation of regulation from 
leadership.  
The survey asked respondent organisations for data 
concerning agreed definitions, or scope of practice, for 
their contextual understanding of advanced or specialist 
practice (see Section 5 of this report for deeper context and 
discussion). Of the 48 countries and territories in this sample, 
23 (47.9%) indicated a country level agreement on a definition 
of “specialisation”.  Table 4 indicates the lead agency or 
organisation for this country level definition, and shows that 
leadership or “ownership” of definitions for specialisation 
lie more or less equally shared (in this sample) between 
professional bodies and government or regulatory agencies 
(35% against 48%).
Table 4: Lead agency for country level definition of “specialisation”.
Those respondents indicating a country level definition, or 
understanding, of the term specialisation (contextualised 
within respective countries) are listed in Table 5. 
Table 5: Countries stating a definition of “specialisation” 
of scope of practice.
In contrast, organisational respondents were asked if 
definitions, or agreed descriptions, of the terminology related 
to “advanced practice” were available at country level. There 
was a 23% response to this question, with 11 countries 
claiming an agreed definition of “advanced practice”, and 9 
countries and territories (19%) providing evidence of defined 
practice that covered “specialisation” and “advanced”. 
Matching the availability of having, at country level, either a 
defined process or acceptance of specialisation or advanced 
practice, 25 countries (52%) report one or the other being in 
place. 
For those countries and territories that do have a defined 
notion of “specialisation” or “advanced practice” there is 
no measurable correlation with capacity, so this does not 
appear to be confined or driven by numbers of pharmacists 
in any particular country. However, there does appear to be 
an association with income level or national GDP, with the 
high-income classified countries having a greater weighting 
on provision or acceptance of formalised specialisation and 
advanced practice (chi2, p=0.025, see Figure 3).
Figure 3: Availability of Specialisation/Advanced definition 
with income levels (n = 48).
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3.5 Frameworks for specialisation 
and advanced practice
A number of countries and territories – 18 (38%) – stated 
categorically that frameworks were available for practitioners 
to use for guidance to describe specialisation (narrow scope of 
practice) or advancement (broader scope of practice). A smaller 
number of countries and territories in this sample also said 
that activity was underway to provide framework guidance; 
in total, 58% (28) indicated that frameworks were available or 
were being developed. Of these, it is striking that 38.5% (10) 
have either used directly, or are adapting, frameworks from 
other countries, which potentially shows a high degree of 
collaboration in progress globally. However, it is apparent that 
high-income countries have a tendency to have developed 
frameworks, or are more likely to do so as shown in Figure 4. 
There is scope here for further collaborative working practice 
between countries and leadership organisations.
Figure 4: Specialisation/Advanced framework development by Income level.
Combining responses, 23 countries and territories (49% of 
valid sample) stated that there was availability of professional 
recognition of specialisation and/or advanced practice 
roles within that country and indicated an award of “titles” 
associated with this and 20 countries (42% of the sample) 
indicated the use of a formal post-nominal for individuals that 
match this professional recognition. 
Examples of these post-nominal titles include:
The responsibilities for awarding professional recognition 
or use of a post-nominal to individual practitioners, in this 
sample, seems mainly to stem from professional leadership 
bodies, with 84% (16) of those countries and territories (who 
indicate a form of professional recognition status) stating 
that either professional leadership bodies (or combined with 
regulators) are the “awarding” organisation, rather than 
government agencies.
3.6 Prescribing as a specialisation
The survey investigated the prevalence of prescribing rights by 
pharmacists. Member organisations were asked if, at country 
level, there existed overt legal provision for pharmacists to 
independently prescribe medicines (‘independent prescribers’ 
and specifically not  “over the counter” medicines). In this 
sample, 9 countries (19%) indicated that legal prescribing 
rights did exist and these are listed in Table 6.
Table 6: Countries indicating legal prescribing rights available to Pharmacists.
The requirement for formal qualifications for pharmacist 
prescribing for these 9 countries indicated that further 
specialist and CPD training was a requirement and for 3 
countries, collaborative practice agreements were also 
required. For at least 5 of these countries, pharmacist 
prescribing rights was also formally linked with recognition 
of specialisation and/or advanced practice.
Country income level (World Bank)
High Income
Upper 
Middle IncomeLower 
Middle Income
Low Income
%
 b
y 
ca
te
g
o
ry
60.0%
40.0%
20.0%
0.0%
Yes
Under development
No
Availability of framework to describe 
specialisation (narrow scope) and/or advanced
pharmacy practice (broad scope)
Country 
Australia
New Zealand
Nigeria
Romania
United Kingdom 
(Great Britain)
USA 
(California)
USA
Post-nominal titles      
Adv. Prac. Pharm. [Advanced Practice Pharmacist]
RegPharmNZ [Prescriber]
FPCPharm [Fellowship of Postgraduate 
College of Pharmacists]
Farmacist Sp. [Specialist]
MFRPS I, MFRPS II, FFRPS  [Advanced Stage I/II 
or Fellow of Faculty Royal Pharmaceutical Society]
APP [Advanced Practice Pharmacist]
CPP [Clinical Pharmacist Practitioner]
BPS [Board of Pharmacy Specialties]
Countries indicating legal prescribing
rights available to Pharmacists
Canada
Ghana
Israel
Namibia
Saudi Arabia
South Africa
United Kingdom
USA
Zimbabwe
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3.7 Benefits of specialisation 
and advanced practice
Respondent organisations were asked to list tangible, 
or visible, benefits of the reasons for specialisation and 
advancement – particularly those related to professional 
recognition processes rather than direct subject-specific 
specialisation (for example, specialist training to become a 
radio-pharmacist).
Respondents were divided on this question, with 49% 
(22) stating that there are clear benefits for having overt 
professional recognition mechanisms at country level; there 
is a close association (at p<0.0001 level) with those countries 
who have introduced professional recognition process 
for advancement and stating clear and tangible resultant 
benefits. Table 7 shows in more detail the categories of benefit 
stated by respondent organisations. Developing career 
pathways is common together with links to remuneration for 
advancement.
Table 7:  Categories of stated benefits for pharmacists.
3.8 Summary
This survey of 48 countries and territories is the first of its 
kind to attempt to look at the variety of specialisation and 
professional recognition for advanced practice worldwide. 
The complexity of data arising from the survey was surprising, 
and will result in further work from FIP Education Initiative to 
support FIP member organisations.
What is clear from this first data set is that professional 
advancement and the recognition of advancement in practice 
is clearly a developing trend worldwide. This can be attributed 
to a number of reasons, such as the increasingly complex role 
of pharmacists, the enhancement of more patient facing roles 
and greater extent of clinical pharmacy with the associated 
risk this entails, and a consequent need to be able to endorse 
professional capabilities. Comparisons and parallels with 
medical practice and the advancement of physicians, for 
example, are notable.  
If we are to become a more clinical profession, with enhanced 
responsibilities and accountabilities for pharmaceutical care 
in clinical environments then clear pathways for workforce 
development, coupled with professional recognition and 
credentialing of practitioners, is a policy imperative. There is a 
clear opportunity for transnational collaboration and further 
opportunities for transnational recognition of advanced 
capabilities for the pharmacy workforce.Enhanced career pathway
Enhanced remuneration
Individual Esteem/prestige
Total
 
 Count
7
11
1
19
%
36.8
57.9
5.3
100
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Key messages of the case studies
Argentina: There are seven recognised specialties, which 
relate to sector of practice (hospital, community, sterilisation, 
industrial, health and legal, nutrition and food analysis, 
biopharmacy). Recognition is via professional bodies, some 
of which have developed formal pathways. Recognition of 
hospital pharmacy as a specialty is the most developed, with 
a comprehensive training programme, a residency programme 
and an agreed model of practice. 
Australia: There is a nationally agreed advanced practice 
framework, which describes practitioner development in all 
sectors of pharmacy practice, along a continuum, with three 
defined levels of advancement. The Australian Pharmacy 
Council is currently undertaking a credentialing of advanced 
practice pharmacists pilot programme prior to a full roll out of 
an advanced practice credentialing programme.
Canada: All major pharmacy associations in Canada are 
working collaboratively to develop a blueprint for pharmacy, 
which will align pharmacy practice with the healthcare 
needs of Canadians. Work is currently underway on a 
needs assessment of specialisation in pharmacy. This will 
include agreement on a definition for the term “pharmacist 
specialisation”.
China: Clinical pharmacy has been recognised and is now 
supported by standardised training through accredited 
training sites. Specialisation in areas such as oncology and 
anti-coagulation is beginning, however there are not yet 
agreed competencies or an accreditation system for this 
activity.
Great Britain | United Kingdom: The professional body in 
Great Britain - Royal Pharmaceutical Society (RPS) provides a 
professional recognition programme for advanced practice. 
The “RPS Faculty provides resources and services to assist 
practitioner development by meeting competencies outlined 
in the Advanced Pharmacy Framework (APF). There are three 
developmental stages of recognition and credentialing 
available to advanced practitioners based on review of a 
submitted professional practice portfolio, peer-assessment 
evidence and scope of practice evidence. Post-nominal 
endorsement is granted by the RPS at each Faculty stage.
India: The Pharmacy Council of India is aiming to advance 
pharmacy practice via development of regulations to define 
aspects of practice. More patient-centred care has been 
facilitated by implementation of PharmD programmes and 
mandatory continuing professional development for all 
pharmacists.
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Ireland: The Irish Institute of Pharmacy has been established 
to enable pharmacists to engage with an approved model 
of continuing professional development. Identification of 
skills required by pharmacists to support national healthcare 
strategies will ensure alignment in future development of 
advanced practice and specialisation. Advanced practice 
frameworks will be developed to reflect requirements for the 
Irish healthcare system.
Japan: There is no standardised pathway for the professional 
recognition of pharmacist specialists currently, however areas 
of more advanced practice are increasing. Currently there is a 
range of credentials available to pharmacists that are awarded 
by professional organisations and educational bodies. The 
Japanese Pharmaceutical Association has developed a life-long 
learning support system, which includes a clinical ladder 
with ten levels of skills development. Support for foundation 
levels (1-5) is currently available, and is in development for 
more advanced levels (6-10), including linking to areas of 
specialisation.
Malaysia: There is currently no formal specialised training 
and recognition, however specialty practice has developed 
in a number of clinical areas. Clinical pharmacists are 
required to undertake mandatory training and observation 
in approved hospitals, and some have the opportunity for 
postgraduate study. The Malaysian Academy of Pharmacy has 
a role to advocate and facilitate provision, credentialing and 
accreditation of specialists and advanced level practitioners in 
pharmacy practice. 
New Zealand: A funded pathway for advanced practice, and 
a number of funded cognitive, collaborative and advanced 
pharmacy services, has been accompanied by government 
policy to support pharmacists’ role in the healthcare team. 
Credentialed services include prescribing, vaccination, 
anticoagulation, and supply of emergency contraception, 
trimethoprim and sildenafil without prescription.
Philippines: Work is underway to develop an advanced 
pharmacy practice framework by revising and adapting 
a framework in use internationally. There is currently no 
licensing of specialist pharmacists, however there are 
workshops available to support pharmacists wishing to 
undertake specialty certification in the USA.  Enhancement 
of professional competence has recently been supported 
with the introduction of mandatory continuing professional 
development. 
Portugal: There are four recognised specialties, which relate 
to sector of practice (clinical analysis, regulatory affairs, 
hospital pharmacy, pharmaceutical industry).Approximately 
14% of Portuguese pharmacists are recognised as specialists. 
The Portuguese Pharmaceutical Society is developing 
a competency-based model to recognise these four areas 
and plans to pilot the framework in one of the recognised 
specialty areas. 
TRENDS AND INNOVATIONS 
CASE STUDIES
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Singapore: Under the current career structure, pharmacists 
working in the public healthcare sector can develop their 
career in either professional, clinical or research tracks, 
and can progress to become advanced practitioners in each 
of these tracks. Accreditation and registration of specialist 
pharmacists is available, and there are scholarships 
to support specialist training.
South Africa: There are four recognised specialties which 
relate to sector of practice (radiopharmacy, pharmacokinetics, 
clinical pharmacy, public health and management). Scopes of 
practice and required qualifications for specialist pharmacists 
and pharmacist prescribers have been developed and are 
expected to be regulated shortly. This has been accompanied 
by enhanced career paths for pharmacists in the public sector
Spain: Pharmacy practice in Spain, including specialisation, 
is largely governed by regulations covering all healthcare 
professionals. The titles of “Hospital” and “Primary Care 
Pharmacists” are exclusive to pharmacists and require training 
as a resident intern pharmacist. Other areas of specialisation 
(e.g. clinical analysis and biochemistry, clinical genetics) 
are multi-disciplinary and have education and training 
requirements. 
Switzerland: The professional society (pharmaSuisse) is 
responsible for providing the programmes and titles for 
recognition and maintenance of federal titles in community 
and hospital pharmacy. Holders of these titles are required 
to undertake continuous professional development. It will be 
now compulsory for pharmacists-in-charge of a hospital or 
community pharmacy to have a postgraduate title. 
USA (California, North Carolina): There are many state based 
differences in the recognition of specialty and advanced 
pharmacy practice. The profession is advocating for 
federal recognition of pharmacists as healthcare providers, 
which would enable payment for cognitive and clinical 
services. Some states have developed innovative advanced 
practice models, and many pharmacists are pursuing board 
certification in a growing number of specialties. 
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Argentina:  Seven recognised specialties 
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Summary
• In Argentina, seven pharmacist specialties were determined         
   by the National Ministry of Health in 2013: hospital pharmacy, 
   community pharmacy, sterilisation, industrial pharmacy,  
   health and legal pharmacy, nutrition and food analysis, 
   and biopharmacy. There are the following formal       
   mechanisms to recognise specialities: 
          • Academic professor related to the specialty, 
          • Written test to pharmacists with five years of practice, or
          • Accredited residency
• Currently only hospital pharmacy and sterilisation have    
   established mechanisms to certify its specialist:  
        
          • AIn 2013, the Argentina Association of Hospital Pharmacy 
             (AAFH) and the Argentina Society for Industrial Pharmacy 
             and Biochemistry (SAFyBI) began the process of formal  
             recognition as certification authorities for specialty  
             in hospital pharmacy and sterilisation          
          • Written test to pharmacists with five years of practice, or
          • Accredited residency
Tools, frameworks and support mechanisms
There are a number of activities that encourage the 
development of hospital pharmacy. Argentina was the first 
country in Latino America to set up residencies in hospital 
pharmacy (1981). Currently, there are hospital pharmacy 
residencies in 28 private and public hospitals across six 
provinces, and in Buenos Aires City.
The AAFH have organised two symposia of Pharmacy 
Education, including an international symposium in 2013, 
in which we defined how to achieve specialty certification 
in Argentina according to international standards. In 2015 
we continue working with the Ministry of Health and 
international colleagues to develop an accreditation 
system for residencies.
In 2014 AAFH, in collaboration with hospital pharmacists, 
established the Professional Standards Model for Hospital 
Pharmacy Services (MPPFH). The challenge remains to increase 
awareness and implementation of these standards.
The AAFH offers an annual course for hospital pharmacy 
(Comprehensive Training Program in Hospital Pharmacy - 
PROCIFH). The first level comprises 485 hours in basic topics 
delivered by virtual education with the support of Pan 
American Health Organisation (PAHO). This level includes: 
management, drug evaluation and selection, clinical, and 
development of medicines in hospital. In 2014 PROCIFH had 686 
pharmacists studying at least one of the four blocks of content. 
The second level of PROCIFH includes: critical care, medication 
reconciliation, medical devices & management in hospital 
pharmacy, and HIV therapeutics. This annual online program 
includes assessments and activity blocks. Its overall objective 
is to update the conceptual and methodological knowledge of 
hospital pharmacists.
Other education sessions offered include an annual congress, 
activities in patient safety, and an annual pharmacovigilance 
meeting. 
These topics allow the integration of pharmacists in health 
teams (mainly in hospitals), an important activity encouraged 
by authorities through quality programs and awards. 
Sterilisation is also recognised as a specialisation for 
pharmacists in Argentina, either in hospital or industrial 
pharmacy. There are university courses in sterilisation and 
different organisations that support its development.
Development of industrial pharmacy is very important in 
Argentina, which leads the production of drugs in Latino 
America. The Argentine Association of Industrial Pharmacy 
holds a prime position in training especially in new 
developments such as biopharmaceuticals. 
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Alignment with national strategies for 
healthcare services and delivery 
The Argentine health system has a strong operational 
decentralisation, and provincial governments are responsible 
for health planning according to the needs of each 
jurisdiction. Due to this decentralisation, the inclusion of 
hospital pharmacy in the strategies of the different local 
health services varies greatly. The accreditation of hospitals 
by the Joint Commission (http://www.jointcommission.org) 
is another important support in hospital pharmacy. 
There are very few hospitals that undertake this process 
of accreditation and so hospital pharmacy in those hospitals 
is recognised and valued. 
There is very good integration in the biggest province, Buenos 
Aires, which has a central commission of hospital pharmacy. 
In Buenos Aires City, private hospitals generally have more 
technology and offer more complex professional services 
than public hospitals. However, there are some public hospital 
pharmacies who offer a high level of pharmaceutical services 
in, for example, pharmacovigilance, clinical pharmacokinetics, 
quality management systems, management of medical 
devices, and IV compounding. Traceability is an official 
regulation, which requires hospitals to develop Unit Dose 
Distribution Systems. Public primary care programs encourage 
pharmaceutical care in HIV and other chronic diseases in 
hospital pharmacies.
Supporting regulation
          • Resolution 241/00. Standards of organisation and   
             operation of pharmacies in health care facilities;
          • Resolution 1023-2012. Minimum requirements for   
             services and areas of hospital pharmacy. National   
             Quality Assurance Program;
          • Resolution 1086/13 Recognises specialisation 
             in pharmacy’s profession; 
          • Resolutions 3683-11, 1881-12, 247-13, 963-2015 Drugs   
             traceability application in Hospital Pharmacy;
          • Resolution 2303-2014 Traceability of medical products;
          • Resolution 209/ 1996 and Sterilization Standards   
             (modified 102-2008).
Professional recognition
The Argentinian Ministry of Health, and its scientific societies 
or professional associations/boards, award pharmacists’ 
specialist certification.
Ongoing progress
In 2014 the AAFH developed the Model of Practice in hospital 
pharmacy, and during 2015 developed an evaluation 
instrument. In November 2015, to recognise excellence 
in implementation of the Model of Practice, the AAFH will 
present the inaugural Best Related Initiative Award at the 
Annual Meeting of the Hospital Pharmacy Section.
The Professional Standards Model for Hospital Pharmacy 
Services (MPPFH) is a consensus on the skills, knowledge 
and competencies that a hospital pharmacist should have 
to comply with certain provisions with the aim of ensuring 
the provision of individualised, safe pharmacotherapy, which 
is cost effective, and based on the best available scientific 
evidence in hospitals and related care system.1
In 2016 it is expected the assessment tool for the MPPFH 
will be implemented and validated.1
The AAFH offers an annual course for hospital pharmacy 
(PROCIFH), which is described above.
Lessons learned
The Ministry of Health Resolution 1086/2013 was an important 
step to enable implementation of specialty certification. This 
directive will allow the recognition of pharmacist specialties 
in different practice environments and it is essential for the 
beginning of the certification process.
Hospital pharmacy is the most developed specialty, with 
a consolidated system of pharmacy residency at the 
postgraduate level. Currently the residencies are not 
accredited and graduates of the residency programmes cannot 
access the formal title of ‘specialist’. 
A pharmacist may become a ‘Specialist in Sterilisation’ after 
completing two or more years of postgraduate training in a 
university centre of sterilization. This modality for reaching 
specialist certification is not currently effectively implemented 
in Argentina. 
The development of Standards of Practice for hospital 
pharmacists and the definition of a Model of Practice are 
expected to promote similar actions in other pharmacist 
specialties. In Argentina, each jurisdiction has different 
professional realities and regulations, with different ways 
of practice. Therefore, the effective application of a Model of 
Practice, including minimum standards, will have a favourable 
impact on practice, shortening these inter-jurisdictional 
differences.
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Formal recognition of the professional associations as 
certification authorities for specialty in hospital pharmacy 
and sterilization needs to be effectively implemented for other 
areas of specialisation. Similarly, it is necessary to achieve a 
common legal recognition in all jurisdictions of the country.
It is important that health authorities stimulate the 
formation of specialists. The professional organisations and 
other educational institutions should continue working in 
education, accreditation and certification to achieve optimal 
outcomes with the professional recognition of specialisation.
Key stakeholders
Institutions involved in the recognition for advanced practice 
and specialisation are Ministry of Health, Universities and 
Associations (e.g. AAFH, SAFYBI). 
References
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Australia: Nationally agreed advanced 
practice framework
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Summary
• The impetus for an advanced practice framework grew from 
the review of the National Competency Standards Framework 
for Pharmacists in Australia in 2010. 
• In 2011, the Advanced Pharmacy Practice Framework Steering 
Committee (APPFSC) was established with representative 
membership of pharmacy organisations (Australian 
Association of Consultant Pharmacy, The Australian College of 
Pharmacy, Australian Pharmacy Council, Council of Pharmacy 
School Australia and New Zealand, National Australian 
Pharmacy Students’ Association, Pharmaceutical Defence 
Limited, Pharmacuetical Society of Australia, Pharmacy Board 
of Australia, Professional Pharmacists Australia, The Pharmacy 
Guild of Australia, The Society of Hospital Pharmacists of 
Australia) in Australia. 
• The APPFSC developed the Advanced Pharmacy Practice 
Framework (APPF). This was released in October 2012.
• The APPF was designed to be sufficiently flexible to serve as a 
template for describing advanced practice expectations in all 
areas of professional practice (as seen in Figure 1). 
• In December 2013, the Australian Pharmacy Council (APC) 
was endorsed via the APPFSC as the independent entity being 
responsible and accountable for the credentialing of advanced 
practitioners in Australia.  
• In 2015, APC began a Credentialing of advanced practice 
pharmacists pilot programme, to test the APPF and APC 
policies/procedures prior to implementing a full roll out 
of an advanced practice credentialing programme.  
• One hundred and thirty-eight Expressions of Interest were 
received from pharmacists wanting to be part of the pilot. Fifty 
were selected to participate. The participants were selected 
across a broad range of pharmacy practice environments (e.g. 
hospital, community pharmacy, industry, research, education).
Figure 1:  Domains for demonstrating advanced practice in Australia within 
an individual’s scope of practice for the purposes of credentialing.
Profession’s scope of practice
(as reflected by the Pharmacy Board definition of practice)
Any role, whether remunerated or not, in which the individual uses their skills and 
knowledge as a pharmacist in their profession. Practice is not restricted to the provision 
of direct clinical care. It also includes working in a direct, non-clinical relationship with 
clients; working in management, administration, education, research, advisory, 
regulatory or policy development roles; and other roles that impact on safe, effective 
delivery of services in the profession.
Advanced Pharmacy Practice Framework
The five domains for demonstrating advanced 
practice, where Expert Professional Practice 
refers to a particular field or subject in which 
an individual has acquired the knowledge, 
skills and experiences for them to be accepted 
as an expert.
Individual’s scope of practice
A time-sensitive, dynamic aspect 
of practice which indicates those 
professional activities that a 
pharmacist is educated, competent 
and authorised to perform and for 
which they are accountable.
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Tools, frameworks and support mechanisms 
The Advanced Pharmacy Practice Framework (APPF) for 
Australia was based on the UK CoDEG Advanced and 
Consultant Level Competency Framework and adapted for 
Australian needs. 
 
The Australian Pharmacy Council (APC) undertook a literature 
review of advanced and extended practice in pharmacy and 
other health professions in 2013. This project informed the 
development of a contemporary and sustainable pathway 
for recognition of pharmacy practitioners in extended and 
advanced practice roles See Advanced and Extended Pharmacy 
Practice - an environmental snapshot. 
In February 2015, the APC developed:
          • Evidence Guide - evaluation and credentialing 
             of advanced practice pharmacists; 
          • Application form - credentialing of advanced 
            practice pharmacists. 
Both documents were prepared for the APC Credentialing of 
advanced practice pharmacists pilot programme. 
The APC Evaluation Standards, Policies and Procedures and 
Evidence Guide were developed through a process involving 
two rounds of stakeholder consultation.
Alignment with national strategies 
for healthcare services and delivery
A fundamental premise of effective health care is the provision 
of services that meet the needs of the public. When these 
needs change, appropriate modification to the type and 
manner in which health care services are delivered is required.
Credentialing of advanced practice is not intended to be 
applied in a way that restricts or constrains the delivery of 
professional services. The credentialing of advanced practice 
pharmacists will provide a pathway for pharmacists to 
progress to a more prominent place as an expert in medicines 
use, recognised and respected by other health professions and 
the public, and encourages a culture of lifelong learning and       
on-going professional development.
Requirements for CPD/CE
The mandatory requirements for continuing professional 
development (CPD) for all registered pharmacists in 
Australia are specified in the Pharmacy Board of Australia’s 
Pharmacy CPD registration standard. However, there are no 
specific requirements that link CPD to advancing practice or 
specialisation recognition. Of course, if pharmacists do not 
meet the CPD expectations as specified in the registration 
standard then their right to practise is at risk. It is expected 
that anyone pursuing advanced practice recognition would 
undertake CPD over and above that required for continuing 
registration. 
There is also no formal academic pathway to specialisation 
and/or advanced practice in Australia, though it is envisioned 
that pharmacists who achieve the credential of Advanced 
Practice Pharmacist will have postgraduate qualifications.
Supporting regulation
The Australian Health Workforce Ministerial Council (AHWMC) 
has previously provided guidance to National Boards who 
are the regulators of healthcare professions in Australia 
(including the Pharmacy Board of Australia), on the approval 
of specialities in a health profession for the purposes of 
specialist registration under the National Registration and 
Accreditation Scheme. The AHWMC agreed that for approving 
specialties a case for action must be established and a range 
of feasible policy options considered, including self-regulation, 
regulatory and non-regulatory approaches, and their benefits 
and costs assessed. Consistent with this guidance, there is no 
regulation by the Pharmacy Board of Australia in recognising 
advancing practice and specialisation.
Professional recognition
The APC Credentialing of advanced practice pharmacists pilot 
programme will recognise the first wave of pharmacists in 
Australia with the credential of Advanced Practice Pharmacist. 
The post-nominal that will be used is Adv Prac Pharm. The 
duration of the credential is currently being determined. The 
APPF has three potential levels for professional recognition: L1 
(Transition); L2 (Consolidation); L3 (Advanced).
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Ongoing progress
The APC is undertaking (from January 2015 - September 2015) 
an initial pilot programme of credentialing of advanced 
practice pharmacists that will see the first wave of 
pharmacists credentialed in Australia. Candidates for 
recognition of advanced practice must prepare a practice 
portfolio for evaluation by a credentialing evaluator panel 
(each panel has three evaluators). Governance is by the APC 
Advanced Practice Credentialing Committee.
Timelines
April 2015:                   Submission of practice portfolios;
May 2015:                   Training of credentialing   
                    evaluators;
May – June 2015:                   Evaluation of portfolios;
June – July 2015:                   Portfolio interviews; and
August – September 2015:    Outcome notifications to pilot  
                   participants.
Lessons learned
Positives:
     • A united commitment from pharmacy organisations 
        in  Australia to establish a steering committee and
        work together to develop an Advanced Pharmacy Practice     
        Framework for Australia (via the APPFSC).
     • Agreement of the pharmacy organisations to support   
        a model for recognition of advanced practice
        and endorse the APC as the independent entity 
        for credentialing of advanced practice pharmacists.
     • Enthusiasm for recognition of advanced practice by 
        the profession and support from member
        organisations, as reflected by support for the 2015   
        credentialing pilot.
     • Member organisations as ‘readiness support organisations’       
        (RSOs) for their members, working together with APC.
     • Profession-wide consultation process and feedback on APC  
        guidance documents, policies, procedures and standards  
        that will be used for credentialing of advanced 
        practice pharmacists.
     • Preparation of guidance documents and forms for the 2015  
        credentialing pilot e.g. Evidence Guide.
     • A demonstration of the breadth and depth of the pharmacy    
        profession as reflected by the mix of pharmacists selected  
        for the pilot programme.
     • Relatively smooth roll-out of pilot programme.
Challenges:
     • “Genericising” the APPF in order to ensure its practical   
        application for credentialing of advanced practice   
        pharmacists from potentially all practice environments  
        and expert areas.
     • The pilot programme has chosen participants along 
        all points of the advanced practice continuum to test that  
        the APPF and associated APC policies and procedures can         
        properly differentiate those that should be recognised 
        at L1 (Transition); L2 (Consolidation); L3 (Advanced)        
        However, it is clear that those likely at L1 and possibly 
        L2 need a lot more support to prepare a practice portfolio   
        for evaluation.
     • Introducing new terminology and concepts (e.g. the   
        concept of using practice portfolio for evaluation) and  
        enforcing mandatory requirements such as the inclusion 
        of multi-source feedback in practice portfolios.
     • Consistency in provision of information between APC 
        and the RSOs.
     • Developing a robust and valid practice portfolio 
        evaluation process.
     • Timelines for the pilot and the volume of work 
        for participants to prepare a comprehensive 
        practice portfolio.
     • Defining scope of practice and area of expert professional   
        practice - it is clear that advanced practice applicants   
        have broad expertise in leadership, research, education    
        and communication, and are not just experts in ‘oncology’  
        or ‘diabetes’.
     • Communicating the message that the recognition process  
        supports professional development; those evaluated 
        at L1, or L2 have not ‘failed’ but will be provided peer   
        advice on where to focus their professional development  
        in order to pursue advanced practice recognition in future.
Key stakeholders
The pharmacy organisations are the key stakeholders, via 
an all of profession representative committee known as 
the Pharmacy Practitioner Development Committee (PPDC 
- formerly the APPFSC). The regulator (Pharmacy Board of 
Australia) is a member of the PPDC. 
The implementation of the credentialing programme for 
advanced practice pharmacists, is being driven by the APC, the 
independent accreditation, and credentialing organisation.
Once the pilot program is completed in 2015 and the 
evaluation results released, the pharmacy organisations will 
need to actively support the recognition of advanced practice 
more broadly through marketing and promotion to the 
profession, and not just via the PPDC.
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Summary
• Extended practice pharmacists and pharmacists with 
advanced prescribing authority exist in Canada, however there 
is no official definition for advanced practice or pharmacist 
specialisation.
• So far, pharmacists in Canada are encouraged to pursue 
certification by the Board of Pharmacy Specialists (BPS) in the 
USA if pursuing specialisation. 
• In 2014, the Canadian Pharmacists Association and the 
blueprint for pharmacy outsourced a needs assessment of 
specialisation in pharmacy in Canada.  
• Ensuring all pharmacists and key stakeholders (regulators, 
academia, employers, other healthcare professionals, patients 
etc.) have a straight forward definition for pharmacist 
specialisation is crucial before additional work can occur in 
Canada.
Tools, frameworks and support mechanisms 
The blueprint for pharmacy is a collaborative initiative 
between all the major pharmacy associations in Canada. It is 
led by the Canadian Pharmacists Association (CPhA) and aims 
to catalyse, coordinate and facilitate the changes required 
to align pharmacy practice with the healthcare needs of 
Canadians. 
A blueprint for pharmacy Steering Committee helped to 
develop an implementation plan to support the achievement 
of the Vision for Pharmacy in Canada: Optimal drug therapy 
outcomes for Canadians through patient-centred care.
The Canadian Council on Continuing Education in Pharmacy 
(CCCEP) agreed to take a leadership role in the implementation 
of the Key Actions 1.4 (Lifelong Learning) and 1.7 (Continuing 
Professional Development and Continuing Education - CPD/
CE) of the blueprint for pharmacy implementation plan and 
co-hosted a CPD/CE Policy Summit in 2010 with the Canadian 
Pharmacists Association. At this summit, eight Action Ideas 
were identified for implementing the framework and system 
for recognition of specialisation and specialty areas of 
pharmacy practice.
        1. Key stakeholder meeting to define and describe key  
            concepts such as special area of practice and specialty  
            and to develop a schedule for implementation; 
        2. Development of a white paper on credentialing and one 
            specialising in pharmacy; 
        3. Conduct needs assessment for certification and   
            recognition of specialties; 
        4. Develop a funding model; 
        5. Meeting with national certification bodies to engage and  
            get buy-in;
        6. Meeting with educators to discuss role and get buy-in; 
        7. Communication strategy to inform pharmacy               
            professionals, public, etc. about the value of special areas  
            of pharmacy practice and how they would benefit from     
            its implementation;
        8. Establishment of pharmacy special area of practice and  
            specialisation certification system. 
These Action Ideas are being followed up by the blueprint for 
pharmacy Steering Committee.
Alignment with national strategies for 
healthcare services and delivery
The blueprint for pharmacy is a long-term initiative designed 
to catalyse, coordinate and facilitate the changes required 
to align pharmacy practice with the health care needs of 
Canadians. The Vision for Pharmacy is: “Optimal drug therapy 
outcomes for Canadians through patient-centred care” 
(http://blueprintforpharmacy.ca/about).
Supporting regulation
There are limited regulations in place for specialist or 
advanced practice pharmacists in Canada. Two Canadian 
provinces have regulations in place for “advanced practice” 
pharmacists. 
There is one for extended practice pharmacists in the 
Canadian Province of Alberta, where pharmacists can apply 
to the provincial pharmacy regulatory body for  “additional 
prescribing authorisation”. 
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The process is tightly regulated and pharmacists must meet 
strict criteria to receive this extended practice designation 
(e.g. at least one year of experience working in a collaborative 
clinical team, additional clinical training, etc.).  The additional 
prescribing authorisation allows the pharmacist to prescribe 
almost any medication, except for narcotics and controlled 
substances.
In Manitoba, pharmacists may obtain “extended practice 
authorisation”. Extended practice pharmacists are required 
to practice in a specialty area and provide satisfactory 
evidence of specialisation through qualifications listed in the 
regulations.
Further details on the extended scope of practice pharmacists 
can do in Canada can be found here:
http://www.pharmacists.ca/index.cfm/pharmacy-in-canada/
scope-of-practice-canada/     
http://www.cmaj.ca/site/press/cmaj.121990.pdf
Professional recognition 
Upon completion of a residency, the resident may use the 
title designation of ACPR (Accredited Canadian Pharmacy 
Resident). All residency programs are accredited by a national 
accrediting agency.
Some clinical pharmacist jobs are now expecting the 
candidate to have completed a residency (financial incentives), 
but this is a minority of workplaces. 
Ongoing progress 
The on-going work is being performed under the auspice of the 
blueprint for pharmacy
• In 2010, the CPD/CE Policy Summit project identified a 
main action idea was to conduct a needs assessment for 
certification of specialities in Canada. 
• In 2012, a Task Group on Specialisation in Pharmacy in Canada 
was established.
• In 2014, The CPhA called for a request for proposal for a needs 
assessment of specialisation in pharmacy in Canada.  
Since then, a mixture of interviews and surveys has since 
been conducted for this needs assessment of specialisation in 
pharmacy in Canada. 
Lessons learned 
• Recognition for pharmacy specialisation has been largely 
driven by pharmacists themselves.
• The drive for pharmacist specialisation needs to be based 
on improvements to patient care and/improved efficiencies 
within the health system.
• The term ‘pharmacist specialisation’ is used in a wide variety 
of contexts and no single definition is agreed upon in Canada. 
Ensuring all pharmacists and key stakeholders (doctors, nurses, 
patients and administrators) have a straight forward definition 
is crucial before additional work can occur in Canada.
• There needs to exist a distinction between pharmacist 
specialisation and advanced practice.
• Although many pharmacists support the development of 
a Canadian-specific accreditation program for pharmacist 
specialisation, given the size of Canada’s pharmacist 
population, it may be more viable to use international 
certification bodies instead of creating a Canadian-specific 
one.
Key stakeholders
 
Blueprint for pharmacy (http://blueprintforpharmacy.ca/).
Professional organisations: Canadian Pharmacists Association 
(CPhA), Canadian Council on Continuing Education in Pharmacy 
(CCCEP), Pharmacy Examining Board of Canada (PEBC), 
Canadian Society of Hospital Pharmacists (CSHP), Provincial 
Pharmacy Regulatory Authorities, National Association of 
Pharmacy Regulatory Authorities (NAPRA).
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and supported by standardised training
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Summary
• After introducing the concepts of clinical pharmacy 
in the1970’s and pharmaceutical care in 2000 in China, 
pharmacists are expected to provide patients with 
professional instruction on proper administration and caution 
for medications, and to provide advice to physicians with 
therapeutic drug monitoring and necessary adjustment on 
dosage regimens, especially for those patients with impaired 
renal function or hepatic function.
• After prolonged effort, the concepts of clinical pharmacy 
and clinical pharmacists were officially recognised in 2002 
(Provisional Rules of Pharmaceutical Affairs Management 
of Medical Institutions) and 2010 (Pharmaceutical Affairs 
Management of Medical Institutions).
• More recently pharmacists have been encouraged to practice 
in several specialisations including Total Parenteral Nutrition 
(TPN), anti-coagulation, Intensive Care Units (ICU), oncology, 
and pneumology.
• In order to maintain standardised training of clinical 
pharmacists, the Ministry of Health issued a guideline on 
training and accredited nearly 100 qualified training sites 
nationally. 
Alignment with national strategies for 
healthcare services and delivery 
The Chinese government promotes rational use of 
medications, especially antibiotics. Pharmacists were found 
to play active roles against irrational use of medications, 
e.g. higher dose or longer duration, improper medication 
or intervals, etc.  Therefore, pharmacists are encouraged to 
review prescriptions and medical orders in order to prevent 
improper use of medications since 2012.
Requirements for CPD/CE
Pharmacists are encouraged to undertake CPD and are 
required to get a certain number of credits each year. These 
can be gained in a variety of ways including attending 
conferences, seminars or training courses. These activities are 
not linked to university yet. 
Ongoing progress 
There is a need for the following key factors to be present to 
support development of professional recognition:
         • Clear standards to describe and evaluate specialisation      
            competencies;
         • A clear evaluation and accreditation system;
         • An authorised accreditation institution; 
         • Qualified evaluators who have the requisite education  
            background and practical experience;
         • A demonstrated need from patients and physicians;
         • A series of exams and reviewing books; 
         • Textbooks and guidelines need to be translated into   
            Chinese so it becomes more accessible for pharmacists  
            to read and implement best practice.
Lessons learned 
Some of the lessons learned during this process are that 
hospital pharmacists already provide pharmaceutical care. 
The curricula in pharmacy schools and universities are out 
of date so that the capacities of graduates cannot meet the 
contemporary needs of hospital pharmacy. 
Key stakeholders
Professional organisations are the major force driving 
development of more advanced practice through professional 
conferences, seminars and training courses.
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Summary
• RPS members have access to a range of resources and 
services that support their professional development and 
help them meet the behavioural competencies outlined in the 
Advanced Pharmacy Framework (APF).
• Stepping up to the challenge of meeting changing patients’ 
needs requires support and opportunities to develop and 
provide evidence of excellence. This is the role of the Royal 
College in partnership with the profession itself.
Tools, frameworks and support mechanisms 
The RPS has developed its own resources building on work of 
the Competency Development and Evaluation Group (http://
www.codeg.org/). These now extend to handbooks, guidance, 
support tools and standards.
The RPS Faculty provides the professional recognition 
programme of advanced practice across Great Britain and 
(starting in) Northern Ireland. The RPS Faculty provides 
pharmacists with support networks, access to experts 
and mentors across all sectors, and at all stages of their 
professional careers, alongside opportunities to develop 
professionally, to build a portfolio of transferable knowledge 
and skills that is widely recognised. Available to RPS members 
who have completed their first two to three years of practice 
post registration, the Faculty supports them throughout the 
whole of their career as a more advanced practitioner.
RPS members have access to a range of resources and services 
that support their professional development and help them 
meet the competencies outlined in the APF, including:
• a suite of Faculty resources to support professional         
   development and advancement within the Faculty;
• professional curricula spanning clinical, specialist, generalist   
   and science, and generic areas such as management,      
   leadership, mentoring and support and, research and 
   evaluation;
• a portfolio to enable recording of professional development,  
   which is then submitted as part of a portfolio review.
Once a pharmacist’s development has been assessed and 
recognised, they receive post-nominals that align to their 
stage of practice (see Table 1). This provides a means of 
demonstrating their professional experience and expertise to 
their patients, the public and their employer.
Faculty Stage
Advanced Stage I 
"Established, 
Experienced" Practice
Advanced Stage II 
"Excellent" Practice
Mastery
"Exceptional" Practice
Post-nominals
MFRPSI
MFRPSII
FFRPS
Description
Stage I Faculty member
You are established in a role, performing well, and advanced beyond your foundation 
practice years
OR
Are at a stage of specialisation and advancement beyond your early years of practice.
Stage II Faculty member
You are an expert in an area of practice and are experienced. You routinely manage 
complex situations and are a recognised leader locally/regionally.
Faculty Fellow
You are a nationally recognised leader in an area of expertise (often internationally), 
with a breadth of experience and expertise. You are recognised as a leader in 
community pharmacy; have a business/corporate leadership role; or are a 
business/strategic leader in community. 
Table 1: Faculty stages, descriptions and post-nominals.
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Alignment with national strategies for 
health care services and delivery
In 2010, the RPS started a process of long-term strategic 
planning for a workforce wide professional recognition 
process and scheme. The RPS is in a unique position to provide 
leadership for workforce development that is independent of 
provider organisations, government policy changes and other 
vested interests.
Maintaining professional standards of workforce development 
and providing access to useful quality assured development 
processes are a key function for professional leadership 
bodies. More recently the Report by Robert Francis1, 
considers the responsibility of professions, the professionals 
and the wider workforce. Don Berwick2 followed this by 
recommending:
“Mastery of quality and patient safety sciences and practices 
should be part of initial preparation and lifelong education 
of all health care professionals, including managers and 
executives”
Acknowledging the professional privilege to practice, and 
associated responsibilities, are key when developing tools 
to support and empower the profession to play a key clinical 
leadership role in optimising medicines for the best care of 
patients. Stepping up to the challenge of meeting changing 
patients’ needs requires support and opportunities to develop 
and provide evidence of excellence. This is the role of the Royal 
College in partnership with the profession itself.  
Requirements for CPD/CE
On looking back at the development of continuing 
professional training for health professionals during the past 
25 years, it is of interest to note the long-term impact of the 
Kennedy report3 on all health care practice. The requirement 
of pharmacists, doctors, and all other health professionals, 
to demonstrate an active engagement with professional 
development is now required practice. It is salutary to note 
that “professional regulation” as a process usually results after 
a failure in patient care. 
The General Pharmaceutical Council (GPhC) is the regulator for 
pharmacists in Great Britain. Its CPD framework is mandatory 
for all pharmacists who are expected to maintain their 
professional capability throughout their career by keeping 
CPD records. These requirements are the same whether you 
are a member of the RPS’s Faculty or not. There is a potential 
for Faculty membership to be linked to CPD/Continuing Fitness 
to Practice (CFtP) in future, especially as the GPhC moves from 
a set number of CPD records towards a continuous cycle of 
professional development. It is the ambition of the RPS Faculty 
that membership and on-going development within the 
Portfolio will provide the GPhC with the evidence required for 
CFtP. One system for the profession.
Supporting regulation
The only post registration annotation to the professional 
register in Great Britain is for independent pharmacist 
prescribers; these regulations came into effect in 2006. 
A pharmacist independent prescriber may prescribe 
autonomously for any condition within their clinical 
competence. This currently excludes three controlled drugs 
for the treatment of addiction.
In order to qualify as an independent prescriber, pharmacists 
must complete a GPhC-accredited programme.  On successful 
completion of the programme, pharmacists receive a practice 
certificate in independent prescribing, making them eligible to 
apply for annotation on the register.
Professional recognition
Post-nominals are available to Faculty members as recognition 
of their stage of advancement (http://www.rpharms.com/
faculty/faculty-membership.asp). Details are in Table 1 
on page 29.
Ongoing progress
The following six strategic imperatives for the RPS Faculty and 
Foundation Programmes have been identified as essential to 
deliver the potential of the RPS Faculty by 2020. 
Strategic Imperative I: Every member will be supported at 
every stage of their career, through the RPS Foundation and 
Faculty programmes, across all stages and areas of practice.
Strategic Imperative II: Every member will have opportunities 
to develop and advance, and will have support from RPS 
Mentors and Tutors. 
Strategic Imperative III: Every member will have access 
to a roadmap of quality assured education, training and 
development opportunities, mapped to the RPS career stages, 
from Foundation to Faculty, through our accredited provider 
models.
Strategic Imperative IV: Every member will have access to 
support for building their portfolio and gathering evidence 
ready for a quality assured assessment process.
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Strategic Imperative V: The quality of support, development 
and assessment processes will be highly regarded:
     • as a model to support continuing professional       
        development by GPhC (accredited as the gold standard 
        for revalidation / Continuing Fitness to Practice);
     • by employers as a requirement for advanced roles 
        across sectors;
     • by education providers as a route for career support;
     • by other Royal Colleges, professions, regulators,   
        commissioners  and by patients and the public, 
        as a consistent and reliable means of assuring the quality        
        of services provided by Faculty Members and Fellows.
Strategic Imperative VI: The RPS Faculty and foundation 
programmes will be financially viable within the next five 
years, through delivery of quality assured, recognised 
processes of support, development and assessment.
Lessons learned
Submissions to the Faculty are currently based on defined 
deadlines across the year. To improve engagement with 
members of the profession, RPS members will be allowed 
to submit their portfolio at any time throughout the year.
Development and implementation of the strategic 
initiatives (described above) underpins the Faculty’s five 
year strategic approach.
The RPS Faculty and Foundation Programmes support the 
RPS in its wider role in the public health arena through 
campaigning for change, advising government, and taking part 
in national debates on pharmacy, clinical and public 
health issues.
Key stakeholders 
The Royal Pharmaceutical Society in partnership with 
pharmacy specialty groups and members of the profession 
across GB.
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India: Advance pharmacy practice via 
development of regulations  
Author
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Summary
• A Pharm.D course was introduced in 2008 with an emphasis 
on clinical practice, professionalism and training in essential 
professional and generic skills.1  
• Pharmacy Practice Regulations, introduced in 2015 
emphasise patient counselling, pharmaceutical care, 
pharmacy ethics and defining duties and responsibilities 
of pharmacist to the public and profession thus making 
pharmacists accountable to society.2 
• Continuing education is a mandatory requirement for 
renewal of registration.2 
• Diploma in pharmacy is the minimum qualification for 
registration to practice in India. Since 2014 there has been 
an opportunity for diploma pharmacists to upgrade their 
qualification to Bachelor of Pharmacy (Practice).3 
• There are Minimum Qualification for Teachers in Pharmacy 
Institutions defining the number, qualification, experience etc. 
for pharmacy teachers.4 
Tools, frameworks, support mechanisms
The Pharmacy Council of India (PCI) is aiming to advance 
pharmacy practice via development of regulations to define 
aspects of practice such as code of pharmacy ethics; patience, 
delicacy and secrecy; the role of the pharmacist for promotion 
of rational drug use; and pharmacist’s conduct during 
counselling. 
These regulations are designed to ensure good pharmacy 
practice, emphasise highest quality assurance in patient 
care, and define their statutory duties and responsibilities of 
pharmacists thus making them accountable. The ultimate aim 
is to ensure that patients are not neglected by describing the 
obligations of the pharmacist to patients.
Alignment with national strategies for 
healthcare services and delivery
The Indian National Health Policy recognises the significant 
role played by pharmacists, the pharmaceutical industry and 
pharmacy professionals.
The PCI ensures there are a sufficient number of skilled and 
competent pharmacists. Minimum national standards have 
been set, for example:
• The availability of clinically trained pharmacists (after six 
years of PharmD study) has had a positive impact on more than 
60,000 patients who visit more than 200 hospitals associated 
with a PharmD programme. An improvement in the responsible 
use of medicines is of benefit to patients and hospital 
management.
• There has been strengthening of the government 
pharmacovigilence programme and there is now a database of 
adverse drug events being reported. The Pharmacy Council of 
India has been successfully producing well trained competent 
pharmacists to meet the different needs of the country in this 
sector.
It is proposed to utilise additional funding for continuing 
education of pharmacists and to strengthen and upgrade 
pharmacy institutions. Proposals include establishing a 
National School of Pharmacy with the objective of producing 
clinically trained pharmacists who will play a significant role in 
pharmacovigilance in the country.
Requirements for CPD/CE
There is a requirement for continuing education. 
Supporting regulation
       1. Pharmacy Practice Regulations, 2015.
       2. Minimum Qualification for Teachers in Pharmacy   
            Institutions Regulations, 2014.
       3. Pharm.D. Regulations, 2008.
       4. Education Regulations, 1991.
       5. The Bachelor of Pharmacy (B.Pharm) Course Regulations,  
            2014.
       6. The Master of Pharmacy (M.Pharm) Course Regulations,    
            2014.
       7. Bachelor of Pharmacy (Practice) Regulations, 2014.
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Ongoing progress
The vision and mission of the PCI is to continuously evolve 
pharmacy course curriculum towards meeting present and 
future societal needs so as to prepare a pharmacist workforce 
with required competencies.  There is a focus on continuing 
education of in-service pharmacists and pharmacy faculty.
Establishment of National Task Force for Quality Assurance in 
Pharmacy Education to motivate the pharmacy institutions to 
provide more than minimum prescribed standards.
National School of Pharmacy as a centre of excellence.
On-going work includes periodically reviewing the Pharmacy 
Act and regulations to ensure they are contemporary with 
latest developments in the field of pharmacy education and 
practice. 
Working on a common platform with other stakeholders 
for exchange, mentoring and learning with a focus on 
development of leadership skills. 
 
Lessons learned 
1. Successful implementation of the PharmD course has   
    advanced practice by enabling more patient centred care.
2. Maintenance of the prescribed standards by the pharmacy  
     institutions has ensured the quality of the pharmacist 
     workforce.
3. Mandatory continuing education for pharmacists and   
    teaching faculty has helped in enhancing the competencies,  
    knowledge and skills that has benefit all stakeholders       
4. Introduction of new regulations has ensured that   
    compliance to erstwhile guidelines and policies now become 
    mandatory by law. This will help in ensuring and uplifting   
    the standards of pharmacy education and profession.
Challenges
1. Indian pharmacy qualifications are designed to meet the 
varying needs of the country as well as other regions. Hence 
some of the qualifications may be different from those that are 
globally, and may not meet the needs of such countries and 
regions.
2. There is a shortage of pharmacy faculty, in the areas 
of pharmacy practice to provide PharmD students with 
the advanced experiential training. One of the strategies 
with which this can be overcome is by collaboration with 
international universities, to hire their faculty members as 
visiting professors will help in exchange of resources that will 
support the development of the PharmD program in the right 
direction.
3. Community and hospital pharmacists predominantly hold 
a diploma in pharmacy qualification and are now seen to 
be under qualified. The introduction of a bridging course 
will provide an opportunity to pharmacists holding diploma 
qualification to upgrade their qualification to Bachelor of 
Pharmacy (Practice). Similarly, the first cohort of PharmD 
graduates (2014) are now employed in hospitals and this is 
expected to address the requirements of clinical pharmacy 
practice.
Key stakeholders 
The work is done by the regulator, based on the input received 
from various professional associations and other stakeholders 
(e.g. pharmacy institutions, general public). 
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Ireland: Nationally approved model of 
continuing professional development
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Summary
• A CPD system is currently being developed by the Irish 
Institute of Pharmacy, which will require pharmacists, to 
demonstrate generalist competency requirements. In time, it is 
anticipated that this system will evolve to facilitate specialist 
and advanced competency.  
• For the provision of advanced services, such as 
administration of seasonal influenza vaccination, pharmacists 
must undertake additional training, which has been accredited 
by the Regulator.
• The Hospital Pharmacists Association of Ireland is engaged 
with the Health Service Executive to recognise specialism 
within hospital pharmacy. The post of specialist pharmacist 
was first recognised with the appointment of pharmacists for 
hospital based hepatitis C services.
Tools, frameworks, support mechanisms
The development of advancing practice and specialisation has 
largely been a ‘bottom up’ approach with pharmacists seeking 
out postgraduate courses to undertake. The one exception 
to this has been the taught Masters in Hospital Pharmacy 
in Trinity College for which there are six paid positions in 
university teaching hospitals each year. This course has been 
available since the 1990’s.
The representative body for hospital pharmacists has also 
engaged with the employer (largely a state run health system) 
to achieve recognition in job descriptions and posts for 
advanced practice. Agreement was reached in November 2011 
but the agreed structure has not been implemented to date.
The Pharmaceutical Society of Ireland (PSI) is looking at 
hospital pharmacy practice as a priority for 2015. It plans to 
carry out a review to explore and enhance the contribution of 
pharmacy, both community and hospital, to the health system, 
and the safe and effective care of patients, supporting good 
practice in expanded pharmacy services. 
It will engage with stakeholders to progress development 
of hospital pharmacy practice (http://www.thepsi.ie/tns/
publications/CorePublications/publications_2015.aspx).
The Irish Institute of Pharmacy (IIOP, www.iiop.ie) has been 
established to enable pharmacists to engage with the model of 
CPD approved by the PSI. The Institute will deliver an increasing 
range of accredited programmes and will introduce the Quality 
Assurance system component of the CPD model. As the learning 
needs change the IIOP will support the development and 
recognition of advancing practice and specialisation.
Alignment with national strategies for 
healthcare services and delivery
The IIOP will work with the PSI (Regulator) the Department 
of Health and the Health Service Executive (delivery body 
for Health) to identify the skills required by pharmacists to 
support national healthcare strategies. An annual work plan 
for pharmacy CPD programmes will be agreed and signed off 
to ensure that the development of advanced practice and 
specialisation is aligned with national strategies for healthcare 
services and delivery. Similarly, future advanced frameworks 
will be reflective of the requirements of the Irish healthcare 
system.
The hospital structure is currently undergoing re-organisation. 
There will be seven hospital groups to provide services for 
specific regions. It is considered that these groups will provide 
for all the health needs of the population in the region. The 
Report on the Reform of Hospital Pharmacy is currently being 
aligned to the new structures with a view to implementation 
(http://www.hpai.ie/uploads/Review2012.pdf).
Requirements for CPD/CE
This is not yet defined, as advanced practice has not yet 
been recognised in job descriptions. In practice pharmacists 
undertake appropriate CPD to support their practice.
The CPD for Ireland is an outcomes-focused model, which 
involves ePortfolio reviews and practice assessments. The focus 
is on reflective practice, and pharmacists are encouraged to 
undertake CPD activities that are relevant to their practice in 
a way that is appropriate for them. There is no requirement to 
demonstrate completion of hours or courses of training or to 
accumulate points. Instead, completion of an ePortfolio, which 
supports reflective practice, is a central component 
of the system.
ePortfolio reviews: Pharmacists are required to use the IIOP 
ePortfolio to maintain a contemporaneous record of their CPD. 
Pharmacists will be selected at random once in every five year 
cycle and required to provide an extract from their ePortfolio to 
demonstrate that they have been engaging with CPD. 
This extract will need to demonstrate that the pharmacist has 
completed regular self-assessment (using the core competency 
framework) and that they have included a range of CPD records 
which will allow them to meet requirements. 
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These requirements will be set each year by a group of 
peers and it is anticipated that they will evolve over time. 
Requirements will be communicated clearly on an on-going 
basis to pharmacists.  Reviews are carried out by trained peers. 
Reviewers will seek evidence that pharmacists are engaging in 
CPD, in a way that is relevant to their role and which will result 
in enhanced patient care, and which meets the requirements 
that have been set.
Practice reviews: Each year a percentage of pharmacists 
who are in patient-facing roles will be randomly selected 
and required to participate in a practice assessment. This is 
similar to the process which is in place in the Ontario College 
of Pharmacists. Pharmacists will be required to undertake a 
clinical knowledge assessment and to participate in a number 
of simulated scenarios.
Secondary legislation is currently being drafted which will 
give legal effect to the CPD system (http://www.thepsi.ie/
consultations.aspx) which is based on a core competency 
framework (http://www.thepsi.ie/Libraries/Publications/
PSI_Core_Competency_Framework_for_Pharmacists.sflb.ashx). 
However, as more advanced frameworks are developed and as 
specialisation and credentialing evolves, the CPD requirements 
can be expected to evolve to reflect this. 
Supporting regulation
The Pharmacy Act 2007 (Section 7(1)(d)) (http://www.thepsi.
ie/Libraries/Legislation/Pharmacy_Act_2007.sflb.ashx) states 
that the PSI has responsibility for ensuring that “pharmacists 
undertake appropriate continuing professional development, 
including the acquisition of specialisation”. Under secondary 
legislation, which is currently in the process of public 
consultation (http://www.thepsi.ie/consultations.aspx), the 
IIoP is the management body that is responsible for the 
establishment and management of an appropriate CPD system 
to support the development of pharmacy practice.
Ongoing progress
Although Ireland has not yet developed a formal programme 
of specific professional development to assist pharmacists 
in evolving their advanced and specialised practice, the 
PSI has established the IIoP to oversee the development 
and management of the CPD system for the pharmacy 
profession in Ireland. The PSI will work with the IIoP in any 
future development of the accreditation and recognition of 
specialisation in the pharmacy profession.  
Lessons learned 
In the absence of a national instruction such as happened in 
the UK, the pharmacy profession will have difficulty as a small 
profession in being heard at the national level.
The publication of the European statements on hospital 
pharmacy has been a welcome development as it sets the 
broad scope of the role of the profession allowing each 
country to progress from a different starting point and can 
be used to elaborate on the potential of hospital pharmacy 
(http://www.eahp.eu/practice-and-policy/european-
statements-hospital-pharmacy).
Hospital pharmacists avail of on-going academic courses to a 
very significant degree and this attitude has helped to drive 
practice and standards in the interest of patient care and 
patient safety – this has enabled the “bottom-up” approach to 
the development of advanced practice with hospital pharmacy 
– albeit as yet not formally recognised.
The developments in the UK and Northern Ireland have also 
been of assistance – both in terms of practice development 
and educational courses e.g. http://www.qub.ac.uk/schools/
SchoolofPharmacy/ProspectiveStudents/PostgraduateTaught/
PrescribingforPharmacists/  
Key stakeholders 
The development of advancing practice, up until now has 
been driven by a range of bodies including the Regulator, 
representative bodies and pharmacy chains.
In future, the recently established Irish Institute of Pharmacy 
will be responsible for supporting the development of 
pharmacy practice, which will include development and 
recognition of advancing practice and specialisation.
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Japan: Lifelong learning support system 
includes a clinical ladder with 10 steps 
of skills development
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Summary
In Japan, there are some systems for pharmacists’ credentials:  
• Certificated pharmacists through continuing education 
programme.
• Certifying pharmacists through related societies such as 
Japanese Society of Pharmaceutical Health Care and Sciences, 
Japanese Society of Clinical Pharmacology and Therapeutics, 
Japanese Society for Emergency Medicine, Japanese Society 
of Chemotherapy, etc. Other certifying pharmacist is “Sports 
pharmacist” who has a role in promoting prevention of doping 
in athletes.
• Specialist pharmacists are certified by the Japanese Society 
of Hospital Pharmacists in the fields of cancer, infection 
control, psychiatric, HIV infection, pregnancy or lactation etc.
Tools, frameworks, support mechanisms
To support the development of advancing practice and 
specialisation, the Council on Pharmacists Credentials 
(CPC - an independent agency) evaluates and accredits 
Continuing Education Credentialing Programmes, Special 
Training Programmes, and Pharmacy Specialties Credentialing 
Programmes in order to increase pharmacists’ competence and 
professional role.1
Although CPC accredits the pharmacy educational 
programmes, the recognition itself is granted by the relevant 
organisations, including pharmacy-related professions, 
academic fields, and educational bodies in Japan.1
The process and standards vary in each specialty area, and 
these are developed by the awarding organisations.1 For 
example, the Japanese Society of Hospital Pharmacists (JSHP) 
provides some internship programmes to become a specialist 
pharmacist, while the other awarding bodies provide textbooks 
and lectures, seminars or workshops.
The Japanese Pharmaceutical Association (JPA) developed and 
launched ‘JPA life-long learning support system (JPALS)’ in April 
2012 to support continuing professional development (CPD). 
This system currently supports CPD at a foundation level and 
a support system for advancing practice is underway.2
Alignment with national strategies for 
healthcare services and delivery
There is little discussion about pharmacist specialisation 
in national (or regional) strategies for healthcare services 
and delivery. However, due to the advancement of 
pharmacotherapeutics and medical sciences, it is natural that 
pharmacy practices will also advance. In order to maintain the 
quality of advancing practice by pharmacists, a support and 
recognition system for pharmacist specialists is essential.3
The government is planning to establish an ‘Integrated 
Community Care System’ by 2015 to provide life-long healthcare 
for the elderly in the community.4 In this system, pharmacists 
are expected to play an important role to provide effective 
care to the elderly. It will be necessary for pharmacists to 
have advancing skills and expand their professional role to be 
involved in this initiative.
Requirements for CPD/CE
There is no mandated requirement for CPD/CE of pharmacists 
in Japan. However, to be recognised and remain a pharmacist 
specialist, often CPD/CE is mandated by the credentialing 
organisation.5 
There is also no specific requirement relating to university-
linked postgraduate education to be a pharmacist specialist, 
although some universities provide life-long learning education 
for pharmacists.
JPALS developed a ‘clinical ladder’ to classify pharmacists into 
level 1 to 10 by their skills. Currently support for levels 1 to 5 
(foundation level) pharmacists is provided, and support for 
levels 6 to 10 (advanced level) pharmacists is in development 
linking to areas of specialisations.6
Professional recognition
Only the Japanese Society of Pharmaceutical Health Care 
and Sciences certified ‘Oncology Pharmacist’ is a nationally 
recognisable title for pharmacy specialisation.7 Pharmacists 
can also become a board certified pharmacy specialist in a 
particular field.
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Ongoing progress
The Japanese government is going to establish an “Integrated 
Community Care System” by 2015 to provide life-long care for 
elderly people in the community.8 It is expecting pharmacists 
to play an important role to provide appropriate care to elderly 
people in community. There is encouragement for health 
professionals, including pharmacists, to establish “Integrated 
Community Care Systems” in each community. This may be an 
opportunity to progress the development and professional 
recognition of pharmacists.
Further, JPALS for advanced level pharmacists is underway.6 
Lessons learned 
Japanese pharmacists may not be well recognised as 
healthcare professionals in the healthcare system. Some 
do not understand that the separation of prescribing and 
dispensing is necessary for responsible use of medicines 
(in 2012 the rate of separation was approximately 66%). It is 
advocated that the role of pharmacists is one of the keys to 
maintaining the health of community people.
Further, there is no standardised pathway for the professional 
recognition of pharmacist specialists at the moment, although 
the areas of advancing practice are growing. To maintain 
and further improve the quality of the established and 
future advancing practice, clear standards for professional 
recognition for pharmacist specialists would be needed.
Key stakeholders 
There are three main professional organisations of 
pharmacists: Japanese Pharmaceutical Association (http://
www.nichiyaku.or.jp/e/default.html), Japanese Society of 
Hospital Pharmacists (http://www.jshp.or.jp/ - no English page) 
and Japanese Society of Pharmaceutical Health Care and 
Sciences (http://www.jsphcs.jp/ - no English site).
They are mainly driving the development and recognition of 
advancing practice and specialisation of pharmacists.  
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Summary
• In Malaysia clinical pharmacy has been introduced in public 
hospitals since the 1990’s. The first Masters program in clinical 
pharmacy was offered by the Universiti Sains Malaysia (USM) 
in 1992. The graduates take leading roles in developing basic 
and advanced clinical pharmacy practice in the country. 
• Although no formal specialisation training and recognition 
has been established, clinical pharmacists have developed 
practice in certain areas such as paediatrics, psychiatry, 
cardiology, endocrinology, oncology, respiratory, ICU, etc. 
• In 2003 the Certified Smoking Cessation Service Provider 
(CSCSP) programme was introduced by the Malaysian 
Pharmaceutical Society (MPS) and Malaysian Academy of 
Pharmacy (MAP) with the support of the Ministry of Health 
(MOH) Malaysia. Up to 2015, more than a thousand pharmacists 
have gone through this training and become certified smoking 
cessation providers in community pharmacies and hospitals. 
An online CSCSP module was launched in 2009 (http://www.
acadpharm.org.my/index.cfm?&menuid=2).
• Since 2004 pharmacist-managed clinics, known as 
“Medication Therapy and Adherence Clinic (MTAC)” have been 
introduced. The aims of the clinic are to optimise the patient’s 
drug therapy, to increase the patient’s knowledge on diseases 
and the medicines, and to increase the patient’s adherence to 
their medications. The MTACs increase collaboration between 
pharmacists and medical doctors. 
• At present, various MTACs have been created and regularly 
follow up the patients. These include: MTACs in diabetes, 
respiratory, psychiatry, nephrology, neurology, heart failure, 
retroviral disease, haemophilia, psoriasis, rheumatology, 
geriatric and anticoagulant (warfarin). Pharmacists need to 
undergo training before starting to provide these services. 
(http://www.pharmacy.gov.my/v2/ms/entri/perkhidmatan-
medication-therapy-adherance-clinic-mtac.html).
Tools, frameworks, support mechanisms
Pharmacists who provide clinical services have to go through 
training with structured modules developed by the Clinical 
Pharmacy working committee of the Pharmaceutical Services 
Division, MOH. In addition they have to undergo observation 
and hands-on training in appointed training institutions 
(hospitals). The duration of these trainings are normally 2-3 
weeks. Protocols and guidelines have been published to guide 
these pharmacists (http://www.pharmacy.gov.my/v2/ms/entri/
perkhidmatan-medication-therapy-adherance-clinic-mtac.html). 
Trainees who complete and pass the assessment are provided 
with a certificate.
As part of professional development, pharmacists working 
in the public sector are given opportunity to undertake 
postgraduate study up to Masters and PhD levels. As part 
of international partnerships and collaboration, selected 
pharmacists are sent overseas every year for short course 
training in specialised areas such as oncology, palliative care, 
rheumatology, paediatric and anti-coagulant management etc.
Alignment with national strategies for 
healthcare services and delivery
The expected outcomes of the Country Health Policy (10th 
Malaysian Plan) are to ensure provision of, and increase 
accessibility to quality healthcare, and public recreational 
and sports facilities to support active healthy lifestyle. Human 
capital development is one of the strategies outlined to achieve 
these outcomes (http://www.moh.gov.my/images/gallery/
Report/Country_health.pdf).   
The Pharmaceutical Services Division has the task to provide 
more pharmacist experts in specialised areas, such as geriatrics, 
paediatrics, nephrology, oncology, cardiology, etc. This is also 
in line with the human development and strategies in the 
National Medicine Policy 2012 (http://www.pharmacy.gov.my/
v2/sites/default/files/document-upload/buku-dunas.pdf). 
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Requirements for CPD/CE
The Malaysian Academy of Pharmacy (MAP http://www.
acadpharm.org.my/) is the professional body dedicated to 
advancing the potential of pharmacists through education, 
advocacy, research and service towards the betterment of 
society and the nation at large. This is in tandem with the 
mission statements: 
       1. To provide continuing professional development (CPD)
            opportunities in support of lifelong learning among   
            pharmacists.
       2. To provide a platform for effective sharing of knowledge,  
            skills and experience among pharmacy educators,   
            researchers and practitioners as well as policy makers.
       3. To advocate and facilitate provision, credentialing and
            accreditation of specialists and advanced level    
            practitioners in pharmacy practice.
       4. To promote innovations in pharmacy practice, research 
            and education.
Currently, there is no specific requirement related to 
postgraduate education but MAP is preparing to offer tutorials 
for pharmacists planning to sit for the coming American BCPS 
(Board Certified Pharmacotherapy Specialists).
Supporting regulation
Specialisation for pharmacy has not being formalised although 
it has been recognised to be the future plan for the careers of 
pharmacists in Malaysia, especially those working in public 
sectors.
At present the development and recognition of advanced 
practice and specialisation is being regulated by circulars from 
the Pharmaceutical Services Division, Ministry of Health(MOH) 
Malaysia. 
Professional recognition 
The Pharmaceutical Services Division, MOH is currently 
in the process of developing proposals and guidelines for 
professional recognition in two categories:
i) Pharmacy Specialisation 
ii) Credentialing & Privileging 
Ongoing progress
At present, the Pharmaceutical Services Division with 
cooperation from universities and MAP are in the process of 
preparing proposals and guidelines for pharmacy specialisation 
as well as modules for residency programs. The two-year 
residency program is designed to produce clinical pharmacists 
who are competent in providing pharmaceutical care in 
the selected specialised areas. At the start of this process, a 
small number of pharmacists with a PhD in clinical pharmacy 
will be selected to undertake special modules and later will 
be appointed as preceptors to this programme. The target 
timeframe for implementation of the residency program is 
2017, with the first pharmacists accredited as specialists in 
2019. 
The Pharmacy Specialist Accreditation Board (PSAB) will be 
responsible for certifying the successful candidates [the 
residency program will have the duration of 2 years. The first 
6 months there will be a written exam. Subsequently the 
assessment will be from case reports, case presentations, 
research projects and portfolio (log book)], who will be 
rewarded special additional allowances in their monthly 
revenue. 
On the other hand, for credentialing and privileging, the 
Pharmaceutical Service Division has set the criteria for 
application. These may include a duration of practice in a 
specific area and prior training attended in the specialty area. 
The National Credential Committee (NCC) will be responsible for 
vetting their credentials.  
Lessons learned 
In Malaysia, the 1980’s saw a shift from product-oriented 
services to patient-focused care. Since 2000, clinical pharmacy 
has expanded into specialised services that now include 
medication therapy adherence clinics (MTACs), critical care, 
cardiology and many more. The transformation is inevitable 
for pharmacy services in Malaysia to be in line with the current 
developments worldwide.
The Pharmaceutical Services Division, MOH ensures that 
the pharmacy services offered are of good quality and are 
achieving the required standards. Among the measures taken 
include standardisation of practice and expertise development 
programme. Expertise development programmes, which 
are training given to the pharmacists, such as the residency 
programme and the special training for pharmacist-run clinics, 
which are called: Medication Therapy and Adherence 
Clinic (MTAC). 
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Two main challenges:
1. Preparedness of the pharmacists (regarding their 
competence, skills, knowledge and making the change to 
become more patient focus).
2. Recognition and collaboration from the medical doctors and 
other health professionals. 
Key stakeholders 
In Malaysia, advanced pharmacy practice is mostly carried out 
in public hospitals and health clinics. It is mainly driven by: 
       1. The Pharmaceutical Services Division of the Ministry 
           of Health, by endorsing the practice and providing jobs
           (vacancies) in the practice area and training to 
           pharmacists.
       2. The Schools of Pharmacy, by providing the postgraduate 
           training in clinical pharmacy and pharmacy practice   
           research.
       3. The Malaysian Pharmaceutical Society and The Pharmacy 
           Academy, by providing CPD
       4. The institutions (hospitals and public health clinics). 
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New Zealand: Government policy supports 
pathway for advanced practice, 
and credentialed services
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Summary
There has been intentional advocacy by the Pharmaceutical 
Society of New Zealand (NZ) since 2004 to create a funded 
pathway for advanced practice in NZ. This began by creating 
and implementing the Ten Year Vision (2004–2014) and 
advocacy with government to create policy that supported 
these roles.
Documents supporting this include:
• Development of NZ National Pharmacist Services Framework 
2014 – involved consultation with all major pharmacy and 
medical organisations and District Health Boards as funders of 
pharmacy service.
• Vision 2020 – Pharmacists and Doctors Working Together: 
Vision statement to offer a strategic direction for the 
pharmacy and medical professions to work together in an 
integrated and collaborative health practice environment to 
significantly improve patient care and health outcomes.
• NZ government policy: Policy direction to optimise the use of 
medicines and the specific role of pharmacists in this.
• Medicines NZ Strategy supported by Actioning Medicines 
New Zealand Policy documents.
• Confidence & Supply Agreement with United Future Party 
– the implementation of the National Medicines Strategy 
will continue, including the enhanced role of pharmacists 
in medicines management and primary care (Opening of 
Parliament 2014 - Speech from the Throne which laid out the 
key objectives for the new government term.)
Tools, frameworks, support mechanisms
NZ has mainly developed their own resources: 
• Pharmacist Services Framework 20141 - This framework 
comprehensively defines pharmacist services that are 
available for primary care and/or secondary care sector 
use. New service areas in the framework are in addition to 
base mandatory pharmacy services and designed to provide 
national consistency for users of pharmacist extended services. 
Health practitioner competence requirements dictate that all 
pharmacist services must be provided in line with appropriate 
standards as defined by the Pharmacy Council of New Zealand.
• Advanced Trainee Fellowship (ATF) Scheme2 - Financial 
assistance to help health professionals undertake advanced 
training, a specialist qualification or study overseas in a priority 
specialty area (Ministry of Health).
• NZ Hospital Pharmacists’ Association (http://www.nzhpa.org.nz) 
 - established a Workforce Development Working Group to 
develop a career progression pathway including suggested 
qualifications, knowledge, skills and behaviours that are 
expected at each level of practice. Competency frameworks 
have been proposed drawing on the General Level Framework 
(CoDEG, UK); shpaclinCAT (SHPA, Australia).
Alignment with national strategies for 
healthcare services and delivery
The current government policy includes an intentional move 
by government funding agencies away from funding medicine 
supply to funding cognitive, collaborative and advanced 
pharmacist services. This has initially involved implementation 
of the Long Term Conditions Service, which is designed to 
support patients with identified medicine adherence issues to 
become self-managing through the provision of a pharmacist 
medicines management service.
This provides the pathway outlined by the NZ National 
Pharmacist Services Framework 2014 to implement the 
government’s Medicines NZ Strategy outlined in ‘Actioning 
Medicines NZ 2010’ (currently being updated through the 
‘Implementing Medicines NZ 2015-2020’ Policy3), in providing 
funding and support for pharmacist’s role in opportunistic and 
scheduled monitoring and screening, pharmacist prescribing 
and the delivery of Comprehensive Medicine Management 
Services. This includes pharmacists managing optimal medicine 
use, medicine therapy assessment and providing health and 
medicine education.
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 The 2020 Vision Statement developed by the Pharmaceutical 
Society of NZ and the NZ Medical Association offers strategic 
direction for six vision areas underpinned by five-year 
objectives from each profession. The six vision areas are:
1. The Patient’s Healthcare Journey
2. Health Professional Roles
3. A Shared Working Environment
4. Services
5. Professional Competence and Ethics
6. Payment Arrangements for Services
The NZ Maori Health Strategy for the pharmacy profession 
provides a pathway for pharmacists to provide high quality, 
innovative services to improve Maori well-being, by enhancing 
patient care and public health.
Requirements for CPD/CE
There are no specific annual CPD requirements set as part 
of the on-going accreditation for Medicines Use Review 
(MUR), Medicines Therapy Assessment (MTA) and prescribing 
pharmacists.
The specific requirements for CPD/CE for pharmacists offering 
Medicines Management Services (MUR, MTA) changed with 
the introduction of the revised Competence Standards for the 
Pharmacy Profession4 in January 2015. The new Standards have 
a focus on professional integrity and quality improvement, and 
therefore carry the expectation that the pharmacist will:
• proactively review their own performance; and 
• actively participate in personal professional development in  
   the context of their own practice as well as ensuring that the
   Medicines Management Service being offered will also 
   undergo a continuous quality improvement process.
Prescribing Pharmacists
The Standards and Guidelines for Pharmacist Prescribers 
require pharmacist prescribers to “actively participate in the 
review and development of their prescribing practice, and in 
the critical appraisal of information to improve patient care”.5 
In particular to: 
• Participate in CPD to maintain quality of prescribing practice. 
• Participate in quality improvement activities to develop and  
   improve prescribing practice. 
• Access, evaluate and apply information to improve      
   prescribing practice.
Supporting regulation
Pharmacist Prescribing — Medicines Act and Misuse of Drugs 
Act amended to allow this activity.
Reclassification of medicines by the Medicines Classification 
Committee of Medsafe (NZ Medicines and Medical Devices 
Safety Authority) from ‘Prescription Only’ to a defined 
exemption from prescription status or Pharmacist-Only 
Medicine status to enable vaccination and pharmacist supply 
of medicines that require an accreditation or credentialing 
process to supply without prescription e.g. emergency 
hormonal contraception, trimethoprim, sildenafil.
Medicines NZ — Government Policy to ensure progression of 
Pharmacist Services away from solely supply services.
Professional recognition 
Any professional recognition for advanced practice or 
specialisation usually relates to titles e.g. ‘Palliative Care 
Pharmacist’ or ‘Pharmacist Vaccinator’. This may or may not 
attract enhanced remuneration – depending on the employer. 
Credentialed services that are recognised in NZ include:
• Vaccination that requires recertification every two years 
[the vaccination accreditation training and two yearly 
reaccreditation is managed by IMAC (Immune Advisory Centre) 
http://www.immune.org.nz/education-and-training].
• Pharmacist Prescribers and MTA pharmacists who have a 
pre-requisite for a specific PG qualification, but no further PG 
qualifications are required after accreditation.
• Community Pharmacy Anticoagulation Services (CPAMS) 
pharmacists who are required to be reaccredited every two 
years.
• Supply of emergency contraception, trimethoprim and 
sildenafil without prescription following specified training and 
accreditation.
Pharmacists are funded for some specialised services e.g. MTA 
but there is no financial incentive to carry out these roles.
 
Ongoing progress
This has been an intentional on-going activity since 2004, with 
the publication of the Ten Year Vision for Pharmacists (2004–14), 
supported by government policy in Medicines NZ (2007) and 
Actioning Medicines NZ (2010). This has been reviewed and 
extended in Implementing Medicines NZ (2015-2020).
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The Pharmaceutical Society of NZ is managing the 
implementation of the NZ National Framework of Pharmacist 
Services, designed to support initiatives to realise the potential 
of the pharmacist workforce and address the barriers to the 
delivery of innovative pharmacy and pharmacist services.
The provision of Community Pharmacy Anticoagulation 
Services has funded pharmacists for the provision of an 
advanced service and the success of this initiative is opening 
further opportunities for additional services.
The Pharmaceutical Society, on behalf of Health Workforce 
NZ, is undertaking a project to investigate the viability of 
introducing pharmacy accuracy checking technicians into the 
NZ pharmacy workforce. This project (PACT Project) is to provide 
evidence to determine whether the presence of an accuracy 
checking technician will enable a pharmacist to free up time 
to engage in, or expand on, the provision of patient-centred 
services without compromising public safety, or the accurate 
dispensing of medicines.
Lessons learned 
Pharmacists are willing to undergo training for advanced 
and extended roles but much less willing to step out of their 
comfort zone. They find it difficult to manage a culture change, 
and many are still stuck in the ‘dispense and supply’ mode.
This was demonstrated with the initial provision of Medicine 
Use Review Services (in 2006) when hundreds of pharmacists 
were trained (often at their own expense) but did not 
follow through to take up contracts and deliver the service. 
This resulted in many contracts being withdrawn. As a 
generalisation, pharmacist are uncomfortable with marketing 
themselves, and there is also a significant barrier with doctors 
being concerned about pharmacists’ ‘taking over’ some of 
their previously exclusive roles.
Pharmacists also find it difficult to produce and put proposals 
to funders and managers.
This is gradually changing and there has been a marked 
increase in the uptake of pharmacists becoming accredited to 
supply trimethoprim, sildenafil, vaccinations and Community 
Pharmacy Anticoagulant Services (CPAMS).
CPAMS has been a real success story with pharmacists 
consistently producing improved results for patients and this 
has led to a building of confidence and a willingness to provide 
further advanced services by pharmacists and a willingness to 
accept them by doctors. This service is a much admired model 
of integrated primary care.
Any advanced services need to be tied to financial benefits 
for the provider and this is not currently happening in NZ. 
The challenge is knowing that there is future proofed funding 
available for delivering these services and ensuring that the 
services remain viable. This will facilitate and encourage 
change management within pharmacy.
Key stakeholders 
Professional organisations — Pharmaceutical Society of NZ 
and the NZ Hospital Pharmacist Association — have been the 
two main driving forces for development and recognition of 
advanced practice. These two organisations have developed 
frameworks and worked to lobby government organisations 
for changes to enable the necessary policy and regulatory 
changes required for advanced practice and service delivery.
The NZ Pharmacy Council (the regulatory authority for 
pharmacy in NZ) developed the competence and registration 
requirements for the Pharmacist Prescriber Scope of Practice, 
which required legislative change.
Health Workforce NZ (a division of the Ministry of Health) is 
charged with developing the health workforce. It collaborates 
with educational bodies and employers to ensure that 
workforce planning and postgraduate training aligns with the 
needs of current and future service delivery.
Health Workforce also provides government funding for 
innovation through demonstration projects and pilots e.g. 
CPAMS.
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Summary
• The Philippine Senate recently approved a bill, aimed to 
regulate the practice, integrate the profession, and enhance 
professional competence through mandatory continuing 
development and research.
• Currently the Philippines Professional Regulation 
Commission (PRC) Board of Pharmacy is responsible for 
registration and licensing of pharmacists but is not yet 
involved in the ‘licensing’ of pharmacy specialists. 
• The Philippines has no advanced Pharmacy Practice 
Framework is currently revising from another country and 
adapting it according to the country’s needs.
• The Philippine Pharmacists Association (PPhA), in conjunction 
with the American College of Clinical Pharmacy, is currently 
offering a series of pharmacotherapeutic workshops to 
pharmacists who wish to pursue Board of Pharmaceutical 
Specialties certification in the USA.
Tools, frameworks, support mechanisms
The Philippines has no advanced Pharmacy Practice Framework 
but is developing one by revising a currently available 
framework from another country and adapting it according to 
the country’s needs.  
The PPhA has been very much involved in issues concerning the 
pharmacy profession. It has established local and international 
partners and linkages with various government and   
non-government organisations as well as other professional 
associations.
Alignment with national strategies for 
healthcare services and delivery
Pharmacy education in the Philippines is guided by the 
Commission on Higher Education (CHED) Memorandum Order 
CMO 3 (http://www.ched.gov.ph/wp-content/uploads/2013/07/
CMO-No.03-s2006.pdf). 
The CMO ensures that pharmacy education in the country 
meets the health needs of the people through quality health 
services and keeping relevant with the demands of global 
competitiveness. 
Requirements for CPD/CE
The Philippine Senate recently approved a bill that aims to 
regulate the practice of pharmacy, integrate the pharmacy 
profession, and enhance professional competence 
through mandatory continuing development and research 
(information available at: http://www.senate.gov.ph/lis/bill_res.
aspx?congress=16&q=SBN-2436 | http://www.congress.gov.ph/
download/journals_16/J58_2RSS.pdf
The current law requires all registered pharmacists to attend 10 
Continuing Professional Development (CPD) units every year. 
Supporting regulation
The Philippine Commission on Higher Education (CHED) is 
responsible for an on-going paradigm shift to competency 
based learning standards 
The Philippine Professional Regulations Commission (PRC) 
ensures the implementation of the Philippine Qualifications 
Framework (PQF), which is the basic framework used for 
all regulated professions under PRC. The PQF is one of four 
convergent programs designed to address jobs and skills 
mismatch. 
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Ongoing progress
The following are initiatives to ensure development 
and professional recognition of advanced practice and 
specialisation:
1. PDI: The Pharmacy DOTS Initiative (PDI) aims to enhance the 
capability of Filipino pharmacists in the control of tuberculosis.
2. Clinical Pharmacy summit: The PPhA Clinical Pharmacy 
Program is in partnership with the American College of 
Clinical Pharmacy. The program is a series of learning modules 
to develop the clinical competency of Filipino pharmacy 
practitioners in the country towards obtaining an international 
specialty board certification in pharmacotherapeutics.
3. PhilPSP: Philippine Practice Standards for Pharmacists 
(PhilPSP) aims to build capacity among pharmacists and 
support workforce that will enable Filipino pharmacists to 
align with global standards and upgrade the level of practice.
4. TESDA Pharmacy Services National Certificate (NC III): In 
view of the need to strengthen the program of Pharmacy 
Services National Certificate (NC) II established last 2008, this 
was revised and justified to be elevated to NC III in 2014. This 
initiative was in partnership with Technical Education and 
Skills Development Authority (TESDA) and the PPhA.
5. Philippine Pharmacy Act of 2014: The State recognises 
the vital role of pharmacists in the delivery of quality health 
care services through the provision of safe, effective, and 
quality pharmaceutical products, pharmaceutical care, drug 
information, patient medication counselling, and health 
promotion. The pharmacists’ professional services shall, 
therefore, be promoted as an indispensable component of the 
total healthcare system to ensure the physical well-being of 
Filipinos.
Key stakeholders 
The Philippines PRC (Professional Regulation Commission) 
Board of Pharmacy does registration and licensing of 
pharmacists who has finished their Baccalaureate (BS 
Pharmacy and its equivalent) degree.
The Philippine Pharmacists Association, Inc. (PPhA) is the only 
Professional Regulation Commission (PRC) — accredited, 
integrated national organisation of licensed Filipino 
pharmacists. PPhA has been very much involved in issues 
concerning the pharmacy profession. It has  established 
local and international partners and linkages with various 
government and non-government organisations as well as 
other professional associations.
  
PACOP (Philippine Association of Colleges of Pharmacy) is 
composed of institutional members or colleges or universities 
all over the country that offer graduate educational 
programmes with specialisations in areas of practice, such 
as hospital pharmacy, pharmaceutical sciences, industrial 
pharmacy, and community practice.
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Portugal: Four recognised specialties
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Summary
• The Portuguese Pharmaceutical Society (PPS), the regulator of 
the profession has four titles of specialised pharmacists:
              • Pharmacist specialised in Clinical Analysis;
              • Pharmacist specialised in Pharmaceutical Industry;
              • Pharmacist specialised in Hospital Pharmacy;
              • Pharmacist specialised in Regulatory Affairs.
• In order to recognise the specialisations, the PPS has one 
evaluation period per year in each area of specialisation. The 
evaluation period consists of exams, and/or internships and/or 
presentation of a work related thesis.
• The PPS is developing a competency-based model to 
recognise these four areas.
•  A pharmacist can only be a candidate for the evaluation 
period after having at least five years of experience in the 
subject/area/field.
• In 2014, 86% of pharmacists in practice in Portugal were non-
specialists. Of the 14% who were specialists:
              • 793 were Specialists in Clinical Analysis;
              • 247 were Specialists in Pharmaceutical Industry;
              • 617 were Specialists in Hospital Pharmacy;
              • 118 were Specialists in Regulatory Affairs.
Tools, frameworks, support mechanisms
The Portuguese Pharmaceutical Society gives general support 
and help to candidates. The PPS is also available for contact and 
to answer any doubts or information requests by candidates 
throughout the year.
More specifically the PPS also promotes support on the 
following:
For Clinical Analysis Specialisation candidates:
• Candidates should choose a laboratory or laboratories able 
to provide them with the practice according to the internship 
programme/syllabus (handbook). The council of the Clinical 
Analysis Board (chosen and appointed by the PPS) will validate 
the proposal according to the suitability of the laboratory(ies) 
chosen for internship.
• Provision of bibliographic references to help candidates to 
prepare themselves for the exams (tools).
For Hospital Pharmacy Specialisation candidates:
• Provision of bibliographic references to help candidates to 
prepare themselves for the exam (tools).
Under development there is a Competency based model 
with a framework that will fit the existing requisites of the 
specialisation.
Alignment with national strategies for 
healthcare services and delivery
Strategy for the future of the health workforce is still under 
development. Portugal is one of the countries in the Joint 
Action for Health Workforce Planning and Forecasting through 
the Central Administration for the Health System.
Particularly regarding pharmacists specialised in hospital 
pharmacy there is under development the alignment of the 
specialisation awarded by the PPS title and the public sector 
career in hospital pharmacy.
Requirements for CPD/CE
It is not compulsory for specialist pharmacists to continue 
their professional development and education related to their 
specialty area. There are no specific requirements relating to 
postgraduate education.
The completion of the Specialisation Programme grants the 
pharmacist 10 CPD credit points (out of the 15 needing to be 
completed in each five year CPD cycle).
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Supporting regulation
The Specialty Boards of the PPS have regulations 
for the titles of: 
              • Clinical Analysis Specialist
              • Pharmaceutical Industry Specialist
              • Hospital Pharmacy Specialist
              • Regulatory Affairs Specialist
Professional recognition
The specialist title is written on the PPS professional card and 
detailed on the PPS pharmacists’ database.
Examples of professional recognition include:
• Pharmacist specialised in Clinical Analysis – comply with 
legal proceedings that grant them access to the function of 
Technical Director of Medical Biology laboratories.
• Pharmacist specialised in Pharmaceutical Industry – comply 
with legal proceedings that grant them access to be Technical 
Director of a pharmaceutical industry with market introduction 
authorisation for medicines and to be a Qualified Person.
• “Area of Expert professional practice – Phase II Diabetes 
disease management service”:
Between April 2008 and June 2010 the 3rd Agreement on 
Diabetes Programme was in place between the Ministry 
of Health, PPS, National Association of Pharmacies, and 
Association of Pharmacies from Portugal. This Disease-State 
Management service was directed to patients who were 
medicated for diabetes and who were not meeting the 
established therapeutic objectives. 
It consisted of the follow-up of diabetic patients in 
programmed visits to the pharmacy (SOAP methodology), 
between doctors’ appointments, with the aim to detect, 
prevent and resolve Drug Related Problems (DRPs) through 
an intervention at the patient level (information, adherence, 
healthy lifestyle advice) and/or doctor referral, followed by a 
follow-up of the intervention’s results. 
It was delivered only by certified pharmacists who had 
completed compulsory courses on DRPs and pharmaceutical 
intervention, patient and doctor communication, 
merchandising and marketing of services, health checks and 
diabetes. Certified pharmacists were paid 15 €/patient/month, 
75% of which was reimbursed by the National Health System, 
and 25% paid by the patient directly.
• Certification of competencies on vaccination and medicines 
administration: 
In 2007 new Portuguese legislation was passed allowing 
pharmacists to expand their services into a number of areas, 
such as immunization and medicines administration included 
coverage of vaccines outside National Vaccination Scheme. 
A major training drive was launched in 2008 leading to the 
first nationwide pharmacy-based flu immunisation campaign 
during the 2008/2009 flu season. 
In 2013 the PPS published guidelines on Immunization Services 
certification: 
              • Guidelines establishing the minimum requirements 
                 for accreditation of initial training and also for 
                 recertification training.
              • Certification to provide the service include:
                         • Complete initial training;
                         • Complete recertification training every 5 years;
                         • Evidence of continued activity.
The National Association of Pharmacies training model was 
one of the first to be implemented across Portugal with 1,914 
pharmacists and 1,273 pharmacies completed the training                   
(48% of Portuguese pharmacies) in 2014, resulting in a 98% 
patient satisfaction.
Ongoing progress
A competence-based model is under development for the 
specialisations that already exist in the PPS. The framework in 
development will need to fit the specific needs of the existing 
(practicing) professionals.
Further proceedings are planned as follows:
• Develop a competency framework, template and handbook 
   for each specialisation;
• Pilot the framework in one of the Specialisation Programmes;
• Extend the experience to other Specialisations.
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Lessons learned      
The main challenges faced so far by the Specialisation model:
•  Human resources are allocated exclusively to the general 
    management of the Specialisations – one pharmacist and 
    one administrative assistant;
•  There is only one exam period per year/per specialisation;
•  Exam jurors are nominated by the National Board of the 
    PPS after recommendation by specialists assigned by each 
    Specialisation Board Council. The jurors work pro bono.
Special challenges of the Specialisation in Hospital Pharmacy 
and Clinical Analysis under work in a hospital setting of the 
public sector (under the Ministry of Health):
•   At the moment PPS is facing the challenge of having a unique 
    national hospital pharmacist career, together with the 
    Health Ministry and the PPS.
•  Specialisations of pharmaceutical professions that work in a 
    hospital setting can be of hospital pharmacy (if based in the 
    hospital pharmacy) and of clinical analysis (if based in the 
    hospital medical biology laboratory).
•  Careers in the public sector unfortunately do not follow a 
    progression compatible with the PPS specialisation. 
    Currently, career progression for pharmacists within the 
    hospital sector follows a general system for public servants 
    in the health sector.
•  Working towards an alignment between both of these 
    specialisations in the PPS and also career progression that is 
    particular to pharmacists.
Key stakeholders 
The National Board of PPS is the competent authority for the 
pharmaceutical specialisations.
The National Board provides education and training 
through the Councils of each Specialist Board, who organise 
congresses, symposia and meetings targeting specialists, and 
through the National Council for Quality, with training events 
on particular quality practices in each professional setting.
The Councils of each Specialist Board also produce handbooks 
and guides for good practice.
•  Hospital Pharmacy — Handbook on Cytotoxic Handling; 
Handbook on Wound Management Material; Handbook for 
Medicinal Gases; Guide on Good Hospital Pharmacy Practices 
(in production).
•  Clinical Analysis — Norms for the Medical Biology 
Laboratory (updated 2015).
•  Pharmaceutical Industry — Adaptation and dissemination of 
the European GMP and GDP.
•  Regulatory Affairs — Good Regulatory Practices.
The Regional Branches of the PPS also provide general 
education and training opportunities to pharmacists.
The Regional Branches of the PPS also provide general 
education and training opportunities to pharmacists.
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Singapore: Accreditation and registration 
of specialist pharmacists available
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Figure 1: Pharmacy career structure in the public healthcare sector.
Summary
A review of the pharmacy career structure in the public 
healthcare sector (see figure 1) was conducted with a new 
career pathway framework being introduced in 2009. Under the 
new career framework, pharmacists in the public healthcare 
sector can develop their career in either the professional, 
clinical or research tracks, and progress to become advance 
practitioners in each of these tracks. Advanced practitioners 
in the clinical track may seek accreditation and registration as 
specialists.   
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The Pharmacists Registration Act 2007 made provisions for 
the accreditation and registration of specialist pharmacists. 
These include the establishment of the (Pharmacy) Specialists 
Accreditation Board (PSAB) whose functions are to define the 
specialties in the pharmacy practice, and to certify those who 
have met the requisites of both qualifications and experience 
for registration as specialists. 
The Ministry of Health has set aside funding to encourage 
more pharmacists to pursue specialist training. From 2008 
to 2012, funding was provided for 35 scholarships in specialist 
residency training and to support another 43 pharmacists 
in Doctorate and Masters programmes. Most of the returned 
residency scholars have been accredited and registered 
as specialist pharmacists and have helped to establish 
the local PGY1 and PGY2 residency programmes.
Figure 2: Current specialist training framework.
(SPC: Singapore Pharmacy Council)
Tools, frameworks and support mechanisms 
Development of specialist training framework: The American 
Society of Health-System Pharmacy (ASHP) Required and 
Elective Educational Outcomes, Goals, Objectives, and 
Instructional Objectives for Postgraduate Year One (PGY1/2) 
Pharmacy Residency Programs have been adapted and serve as 
reference standards for the curriculum of the National PGY1/2 
Pharmacy Residency programmes. The ASHP PGY1/2 Residency 
Accreditation Standards have been adapted to serve as 
reference standards for the Pharmacy Specialist Accreditation 
Board (PSAB) to accredit the local residency programmes.
Recognition of specialisation: The local pharmacy specialist 
accreditation framework was developed with reference to the 
existing medical and dental specialisation framework. 
Besides completion of the National PGY1/2 Pharmacy 
Residency programmes, the US Board of Pharmacy Specialists, 
Specialty Board Certification or Added Qualification is also a 
pre-requisite for accreditation. The figure 2 below depicts the 
current specialist training framework. 
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Other than the PSAB, various other committees were formed to 
provide governance of the Pharmacy Specialist framework. 
• Residency Policy and Oversight Committee (RPOC): 
     • Chaired by the Ministry Of Health (MOH) Chief Pharmacist  
        with membership comprising all six Residency Programme    
        Directors (RPDs), the Office of Residency Training (ORT)  
        Faculty Advisor and an MOH ex-officio.
     • Roles are to guide RPDs in the development,              
        implementation and refinement of the programmes, 
        including the application process and selection criteria  
        of residents, and to monitor and review the outcomes 
        and deliverables of the respective programmes. 
• Pharmacy Residency Accreditation Committee (PRAC):
     • Comprised of senior pharmacy practitioners well-versed  
        in pharmacy practice, education and training from 
        the public healthcare institutions; 
     • Role to accredit the local residency training programmes. 
• Pharmacy Residency Selection Committee (PRSC):
     • Comprised of senior members of the pharmacy 
        and medical community in the public sector institutions
     • Roles are to evaluate applications from the various            
        healthcare clusters, interview applicants and submit 
        its recommendations to MOH for approval. 
• Office of Residency Training ORT:
     • Role to provide administrative, secretariat and technical   
        support to RPOC, PRSC, and residency faculty members.  
Alignment with national strategies for 
healthcare services and delivery
Building Capacity and Capability – The Ministry of Health 
recognised the need for more specialist pharmacists to 
provide specialised care for complex cases in tertiary hospitals. 
The development and implementation of government-funded 
National Pharmacy Residency Programmes will help produce 
sufficient number of specialist pharmacists to meet the future 
needs of Singaporeans and the health care system.
Requirements for CPD/CE
Specialist pharmacists will need to meet continuing 
development requirements by fulfilling the training hours 
required for specialty-specific CE programmes. 
They must fulfil at least 15 of the total of 50 continuing 
professional education points in their specialty areas within 
the qualifying period of two years to be eligible for renewal of 
their practicing certificates.
With the exception of the grandfathered specialists, all 
applicants for specialist accreditation will have to be a holder 
of the following degree, or its equivalent: Master in Clinical 
Pharmacy or Doctor of Pharmacy from institutions of higher 
learning that offers such a degree that is recognised 
by the SPC.
Supporting regulation
The Pharmacists Registration Act 2007 provides for the 
setting up of a separate register for specialist pharmacists 
and the registration of such specialists. The Act also makes 
provision for the establishment of a Pharmacy Specialists 
Accreditation Board (PSAB) to define the pharmacy specialties 
and to determine the requirements for specialist registration. 
Oncology, cardiology, infectious disease, psychiatry and 
geriatrics are the SPC recognised pharmacy specialties
The Register of Specialists is the record of pharmacists who 
are recognised as specialists by virtue of their qualifications, 
specialised knowledge and experience. Accredited specialists 
must have met the necessary criteria stipulated by the PSAB. 
Professional recognition 
A specialist certificate, in respect of that specialised branch of 
pharmacy, would be issued by the SPC. The title of a ‘specialist 
pharmacist’ would also be conferred. Only pharmacists who 
are registered as specialists in the Register of Specialists are 
allowed to use the title ‘Specialist’. 
Specialist Pharmacists serve as an important member of the 
multidisciplinary care team and provide specialty-specific 
inpatient and or ambulatory care services to contribute to 
improved patient outcomes by optimising pharmaceutical care.
Ongoing progress 
The PSAB is constantly reviewing the need to recognise 
other new specialties in tandem with the healthcare needs 
of Singaporean patients, and to set up the related specialist 
training and accreditation framework in the new specialties. 
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Lessons learned 
Focused and continued stakeholders engagement and 
communication, leadership support and sustainable resources 
are needed to transform the pharmacy workforce and to 
integrate basic, advanced and pharmacy specialist practice 
as an essential part of the model of care for Singapore .
What went well: 
• Professional engagement and support from pharmacy       
   leadership;
• Ministry of Health’s funding and continued support;
• Support and encouragement from public hospital doctors. 
Challenges: 
• Shifting practice landscape leading to changing model 
   of care continues to challenge us to better define the scope 
   of specialist practice; 
• Forging closer collaboration with physicians in delivering  
   patient-centred pharmaceutical care as a cohesive team. 
Key stakeholders
Ministry of Health (regulator); Pharmacy department heads 
of public hospitals; and Doctors in public hospitals.
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South Africa: Development of scopes 
of practice and required qualifications 
for specialist pharmacists 
and pharmacist prescribers
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Summary
• The statutory Pharmacy Council has developed draft scopes 
of practice and qualifications for four categories of specialist 
pharmacists (Radiopharmacist, Pharmacokineticist, Clinical 
Pharmacist and Public Health Pharmacy & Management). 
Finalisation and publication as regulations is anticipated by 
the end 2015. 
• The National Department of Health instituted an 
Occupational Specific Dispensation for scarce healthcare 
skills. This provides recognition and remuneration for 
specialisation as well as a number of career paths for 
pharmacists in the public sector. 
• Community pharmacists may obtain a supplementary 
qualification in Primary Care Drug Therapy. Authorised 
Pharmacist Prescriber regulations, which will permit 
pharmacists to diagnose and treat conditions in compliance 
with the Primary Health Care Essential Medicines List and 
Standard Treatment Guidelines, are awaiting approval and will 
support government strategies to improve health care across 
the country.
Tools, frameworks and support mechanisms 
The development of scopes of practice and qualifications for 
specialist pharmacists and pharmacist prescribers have been 
developed through consultation processes and benchmarked 
with similar internationally recognised scopes of practice and 
qualifications.
Frameworks used:
        1. Council on Higher Education (CHE) - National         
             Qualifications Framework (NQF) – Masters level 
             qualification (NQF9) and Postgraduate Diploma (NQF8). 
        2. Legislation – Education, Health and Pharmacy Acts.
        3. Other specific regulations mentioned in case study.
These Action Ideas are being followed up by the blueprint for 
pharmacy Steering Committee.
Alignment with national strategies for 
healthcare services and delivery
South African national strategies include roll out of universal 
health care through the implementation of National Health 
Insurance (NHI), focus on the primary health care level through 
the Re-Engineering Primary Health Care (PHC) Strategy and the 
National Development Plan (NDP) 2013.
Primary Care Drug Therapy Pharmacists and Authorised 
Pharmacist Prescribers are aligned to Re-Engineering PHC 
approach and improvements in access to health care services.
Clinical Pharmacy and Public Health Pharmacy & Management 
Pharmacists align to new posts recently created (Clinical 
pharmacist and Policy pharmacist, respectively) in public 
sector (government services) through benchmarking processes 
resulting in Occupational Specific Dispensation (OSD) intended 
to improve quality of pharmaceutical services in public sector.
Requirements for CPD/CE
CPD is required for all pharmacists in South Africa and CPD 
relevant to advanced practice and specialisation would be 
required for pharmacists registered as advanced practitioners 
and specialists. Although postgraduate education in these 
fields is largely in the interests of professional development, 
and can therefore be used to meet CPD requirements, the 
only specific requirements are those dictated by the gazetted 
qualification. These are required for registration as a specialist/
advanced practitioner but not for CPD. 
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Supporting regulation
Pharmacists (additional services)
Rules relating to the services for which a pharmacist may 
levy a fee and guidelines for levying such a fee or fees. 
Board Notice 33 of 2012. Pretoria: Government Gazette 
No. 35095, 2 March 2012. URL: http://www.mm3admin.
co.za/documents/docmanager/0C43CA52-121E-4F58-B8F6-
81F656F2FD17/00025238.pdf  
Primary Care Drug Therapy Pharmacist
Draft Regulations relating to supplementary training or 
refresher courses to be undergone or taken by persons 
who are registered in terms of the Pharmacy Act, 1974, and 
the provisions and control over such training or courses. 
Government Notice No. R.1138, 4 August 1995. URL: http://www.
mm3admin.co.za/documents/docmanager/0C43CA52-121E-
4F58-B8F6-81F656F2FD17/00010798.pdf  
Authorised pharmacist prescribers
Draft Scope of practice and qualification for authorised 
Pharmacist prescriber. Board Notice 122 of 2011. Pretoria: 
Government Gazette No. 34428, 1 July 2011. URL:  
http://www.gov.za/sites/www.gov.za/files/34428_bn122.pdf 
Specialist Pharmacists
Draft Regulations relating to the registration of the specialities 
of Pharmacists. Government Notice No. R.2342. Pretoria: 
Government Gazette No. 15658, 29 April 1994. URL: http://www.
mm3admin.co.za/documents/docmanager/0C43CA52-121E-
4F58-B8F6-81F656F2FD17/00011755.pdf  
Draft Scopes of practice and qualifications for specialist 
pharmacists. Board Notice 152 of 2014. Pretoria: Government 
Gazette 38327, 12 December 2014. URL: 
www.gov.za/sites/www.gov.za/files/38327_bn152.pdf 
Professional recognition 
Specialisations
• In public sector (government): through creation of some 
   new  posts for clinical pharmacists and policy pharmacists, 
   at a fairly senior level. 
• In private hospitals: through creation of some clinical      
   pharmacist posts, some of which may be remunerated 
   at an increased salary scale. Pharmacists receive a financial    
   recognition for their advanced practice/specialisation. 
Pharmacist prescribers (Primary Care Drug Therapy 
pharmacists and Authorised Prescribers)
Pharmacists can charge fees for services. 
Other services provided by pharmacists (screening, 
immunisations, emergency contraception etc.)
Pharmacists can charge fees for services.
Ongoing progress 
Advanced Practice: 
Authorised Pharmacist Prescribers: Regulations are awaiting 
signature by Minister of Health.
Specialisations: 
Scopes of Practice and qualifications for Radiopharmacist and 
Pharmacokineticist (existing specialist pharmacists categories) 
and Clinical Pharmacist and Public Health Pharmacy 
& Management (new categories) expected to be approved 
by end 2015.
Providers of new Masters qualifications, which are 
a requirement for registration as a specialist pharmacist, 
are expected to be accredited in 2016.
Lessons learned 
Good support from Minister of Health (government) 
and private health sector for advanced practice and 
specialisations. 
Challenges: Some concerns regarding scope of advanced 
practice, and areas of specialisation have been expressed 
by some professional boards e.g. Health Professions Council 
of South Africa (includes doctors) and South African Nursing 
Council. However, the South African Pharmacy Council (SAPC) 
has developed good relationships between boards and 
memorandum of understanding (MOU) is in place to facilitate 
engagement between boards on matters of mutual concern.
Lessons: Providers of new qualifications will only be accredited 
by SAPC after the new regulations for the qualification are 
published. 
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Key stakeholders
 
Several role players are promoting the establishment of 
advanced practice and specialisation including: South African 
Pharmacy Council (SAPC) (regulator) with support of the 
Department of Health, Pharmaceutical Society of South Africa 
and its sectors (the Academy of Pharmaceutical Science, 
SA Association of Hospital and Institutional Pharmacists, 
SA Association of Pharmacists in Industry, and SA Association 
of Community Pharmacists), South African Society of Clinical 
Pharmacy (SASOCP), Independent Community Pharmacy 
Association (professional organisations) Schools of Pharmacy 
& Public Health (academic institutions), and individual 
practitioners.
The SAPC as the regulator, plays a pivotal role in ensuring 
that the qualification and scopes of practice of the advanced 
practice and specialisations are approved by the Minister of 
Health.
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Spain: Specialisation is largely 
governed by regulations covering 
all healthcare professionals
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Summary
• The specialised training of healthcare professionals is 
intended to provide them with the knowledge, techniques, 
skills and aptitudes required for a given specialty. At the same 
time during this training, the professional gradually assumes 
the responsibilities associated with the practice of said 
specialty.
• The regulation of healthcare professions provides Spain’s 
health system with the legal framework containing those 
instruments and resources making it possible to integrate 
healthcare professionals into healthcare services, facilitating 
the joint responsibility needed to achieve common goals, and 
improve the quality of the assistance given. This also ensures 
that all professionals have the skill levels needed to ensure 
citizens’ right to proper healthcare.
Tools, frameworks, support mechanisms 
Primarily the development of the legislation that is applicable 
in each case.
Alignment with national strategies for 
healthcare services and delivery
It is the Spanish government, at the request of the Ministries 
of Education and Health, and subsequent to a report from the 
National Healthcare System Human Resources Commission of 
the National Council on Health Sciences Specialties, and from 
the relevant professional organisation, that defines, deletes 
or changes the names of the titles for Specialists in Health 
Sciences.
The National Healthcare System Human Resources 
Commission, together with requests made by the regional 
governments, the healthcare system’s need for specialists, 
and the available budget, sets the number of places to be filled 
through the annual entrance exams. 
This number is determined subsequent to a report from the 
National Council on Health Sciences Specialties and from the 
Ministry of Education.
Requirements for CPD/CE
In the specific case of the pharmaceutical profession, there 
are no CPD/CE requirements, though practicing professionals 
constantly renew, recycle and obtain new knowledge so as to 
ensure that their professional practice is updated to existing 
needs.
Supporting regulation
As mentioned earlier, primarily:
• Law 44/2003 of 21 November, which defines the healthcare     
   professions [2003].
• Royal Decree 1393/2007 of 29 October, which defines 
   the official university degrees [2007].
• Royal Decree 183/2008 of 8 February, which determines 
   and classifies specialties in the Health Sciences and expounds
   on certain aspects of the system for specialised healthcare     
   training [2008].
• Royal Decree 639/2014 of 25 July, which regulates course            
   subjects, re-specialisation and areas of specific practice,           
   lays out the regulations applicable to the annual tests for   
   admission into training programs and other aspects of the   
   healthcare training system specialising in Health Sciences, 
   and creates and modifies certain specialist titles [2014].
Professional recognition
The specialist title earned (official diploma and denomination) 
is used. In the case of a Doctorate or Masters, the title of 
Doctor in (…) and Master in (…) may be used, as applicable.
Lessons learned
A considerable amount of work has been carried out in this 
area, and the applicable regulations have been completed and 
improved over time. One aspect that needs further work is CPD, 
both for specialised and non-specialised professions.
Key stakeholders
Legislation with support from professional organisations.
57
.................................................................................. ..................................................................................
Switzerland: pharmaSuisse responsible 
for programmes and titles of recognition 
and maintenance of federal titles
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Summary
• Two federal postgraduate titles (community pharmacy and 
hospital pharmacy).
• Postgraduate certificates for specialised competencies.
• Federal accreditation of the postgraduate education of all 
medical professions, including pharmacy.
• Revision of the Law for the Medical professions in favour of 
pharmacists and their evolving role providing new services 
according to the needs of the healthcare system and society.
• The professional association (pharmaSuisse) is responsible 
for all postgraduate education in pharmacy. 
Tools, frameworks and support mechanisms
 
pharmaSuisse developed their own programmes, created 
the necessary infrastructure (external education providers 
and internal education providers) to make the necessary 
postgraduate and continuous education possible and then 
submitted the programs to get acknowledged by the federal 
government. 
The federal Law was adapted after the postgraduate titles 
were acknowledged. 
Alignment with national strategies 
for healthcare services and delivery
pharmaSuisse developed the courses and the postgraduate 
certificates, as well as the postgraduate titles, in accordance 
to the needs of society and the health care system. 
Requirements for CPD/CE
Postgraduate education in Switzerland is not university linked. 
Some or all of the required postgraduate courses can be 
taught at university but only the professional association is 
responsible for delivering postgraduate titles and certificates. 
Postgraduate education has to be further education based 
on the university education. University, postgraduate and 
continuous education is defined in the federal Law for the 
Medical professions (c.f. art. 3: https://www.admin.ch/opc/fr/
classified-compilation/20040265/index.html). 
Every healthcare professional is required to further their 
education by the above law (art. 40). 
Furthermore, every pharmacist holding a postgraduate 
title is required by the postgraduate education regulations 
to further their education by annually visiting four days of 
controlled continuous education, as well as a further six 
days of non-controlled professional reading. These four days 
of continuous education are controlled by the professional 
society, pharmaSuisse, using a specially developed educational 
platform.
Supporting regulation
Postgraduate programs in community pharmacy and hospital 
pharmacy are accredited by federal law every seven years. In 
addition to the accreditation of the programs, the responsible 
institution (pharmaSuisse) will be accredited in 2016 for the 
first time. 
With the accreditation of the programmes in 2013, the 
federal government gave recommendations and compulsory 
amendments that needed to be done within a certain period 
of time (i.e. until the end of 2014 or 2015). The required 
amendments are controlled by the federal government.
Professional recognition
With the newly revised Law of the Medical Professions it 
will be compulsory also for a pharmacist-in-charge to have a 
postgraduate title in either community or hospital pharmacy  
– this is in accordance with medical doctors, dentists and 
chiropractors. The law applies to all pharmacists exercising 
their professional activity in a community or a hospital 
pharmacy.
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Ongoing progress
As mentioned above, the newly revised Law for the medical 
professions was revised in favour of pharmacists and their 
changing role as healthcare professionals providing services 
as required by the evolving healthcare system and the needs 
of society.  
Lessons learned
In 1994-1999 the postgraduate specialisation in community 
pharmacy consisted of two four-week courses over two years, 
organised by pharmaSuisse. In 2000, pharmaSuisse wanted to 
let the pharmacists organise their own schedules according 
to a set curriculum. Now, more than ten years later, and in 
preparation for the first federal accreditation, a set curriculum 
with an organised schedule is back in practice – a mix 
of three single course weeks and single variable courses. 
The curriculum has to be passed within two-five years.
The federal re-accreditation of the postgraduate curricula 
(2018-2020) and the accreditation of pharmaSuisse as the 
responsible organisation for the postgraduate titles in 
pharmacy (2016) will be a large workload but manageable as 
our accreditation in 2011-13 is a model for the re-accreditation 
of the medical professions. In 2016 pharmaSuisse will 
be accredited parallel to the professional societies of 
medical doctors, chiropractors and vets, so that the federal 
government has a comparison among the medical professions.
Key stakeholders
The professional organisation and the federal government.
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USA | California: States differ 
in the recognition of specialty
and advanced pharmacy practice
Author
Sarah McBane, Associate Clinical Professor, University of 
California San Diego, Skaggs School of Pharmacy 
and Pharmaceutical Sciences, smcbane@ucsd.edu. 
Summary
• The diversity of regulatory agencies (e.g. – state boards of 
pharmacy) makes comparison of practices difficult.
• Advanced practice recognition is limited to certain states.
• Specialisation is primarily through the Board 
of Pharmaceutical Specialties.
• The concept of reimbursement for advanced practice services 
remains a challenge.
Alignment with national strategies 
for healthcare services and delivery
In California, it is envisioned that advanced practice 
pharmacists will be able to supplement the primary 
care workforce. Currently, about two-thirds of the counties 
in California lack sufficient primary care physicians.  
While it is not expected that advanced practice pharmacists 
will replace physicians, they may be able to provide care for 
some patients thus alleviating the burden on primary care 
physicians. For example, pharmacists might be able to manage 
medication-intensive conditions such as diabetes, freeing 
physicians to focus their energies on other medical needs. 
Requirements for CPD/CE
In general, pharmacists with advanced practice designations 
have additional requirements for continuing education.  
In North Carolina, pharmacists (without any special 
designation) are required to accrue 15 hours of continuing 
education annually. Clinical pharmacist practitioners are 
required to accrue 35 hours of practice-specific continuing 
education annually. In California, pharmacists (without 
any special designation) are required to accrue 30 hours of 
continuing education every two years. 
Advanced practice pharmacists are required to accrue an 
additional 10 hours of practice-specific continuing education 
every two years. 
There are no requirements for university-linked education. 
State boards of pharmacies will accept continuing education 
accredited by the Accreditation Council for Pharmacy 
Education (ACPE), and some state boards will accept 
continuing education accredited by other bodies. For example, 
California will accept accredited Continuing Medical Education 
(education that would be accepted by the state medical board) 
and also California Accreditation for Pharmacy Education.
Supporting regulation
State regulations are cited above, but there is no similar 
regulation in place at a national level.  
National organisations have published perspectives on 
the need for advanced training and certification, and offer 
educational programmes for their members.
American College of Clinical Pharmacy - publication: 
Qualifications of Pharmacists Who Provide Direct Patient Care: 
Perspectives on the Need for Residency Training and Board 
Certification. Pharmacotherapy 2013; 33(8): 888–891. Available 
at: http://www.accp.com/docs/positions/commentaries/
Commntry_BOR_DPC_phar1285.pdf   
American Society of Health System Pharmacists - policy 0701: 
To support the position that by the year 2020, the completion 
of an ASHP-accredited postgraduate-year-one residency should 
be a requirement for all new college of pharmacy graduates 
who will be providing direct patient care. Available at: 
http://www.ashp.org/DocLibrary/BestPractices/
EducationPositions.aspx 
Professional recognition
Each state has its own laws and regulations regarding 
pharmacy practice. However, many states that have some 
recognition of advanced pharmacy practice recognise the 
certifications from the Board of Pharmaceutical Specialties 
(BPS).
Ongoing progress
In California – as with all states in the United States – 
pharmacists and the practice of pharmacy is regulated by 
our state regulatory body, the state Board of Pharmacy. The 
mission of the Board of Pharmacy is to protect and promote 
the health and safety of California residents by regulating 
pharmacists and pharmacy practice (http://www.pharmacy.
ca.gov/about/mission_statement.shtml). 
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The board has convened a taskforce to evaluate the 
implementation of advanced practice pharmacists. The 
taskforce has met several times, starting in June 2014 
and continuing through the present time. The time frame 
for implementation of advanced practice pharmacists is 
estimated to be in the latter half of 2015. 
Lessons learned
In California, the legislation that created advanced practice 
pharmacists was introduced in 2013. The legislation served as a 
unifying voice for pharmacists throughout the state, especially 
members of the two state pharmacy organisations: ‘California 
Pharmacists Association’ and ‘California Society 
of Health System’.
Current challenges include education of all pharmacists in 
the state – those who are not members of the state pharmacy 
organisations are less likely to be aware of the opportunity – 
and the pace of implementation as regulated by the California 
Board of Pharmacy. An additional challenge is the question 
of reimbursement.  Although pharmacists in California are 
recognised as healthcare providers, there is no legislation, 
policy, or regulation that mandates any sort of compensation 
for advanced practice. 
There are efforts at a national level to garner provider status 
for pharmacists – there are currently companion bills in the 
United States Senate and House of Representatives. These 
bills call for recognition and compensation of pharmacists 
for services not linked to a product (i.e. – dispensing). There 
is no mention of advanced practice pharmacy in these 
bills, however it is implied because the national legislation, 
if passed, would simply authorise and recognise what 
pharmacists do on a state-by-state basis (http://www.
pharmacistsprovidecare.com/facts).
Key stakeholders
In California, the regulator is the current driver. The state 
pharmacy organisations – the California Pharmacists 
Association primarily and to some extent the California Society 
of Health System Pharmacists – are supporting the Board in its 
efforts.
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USA | North Carolina: States differ 
in the recognition of specialty 
and advanced pharmacy practice
Authors
David Steeb, Clinical Assistant Professor and Director of Global 
Engagement, UNC Eshelman School of Pharmacy, david_
steeb@unc.edu; Stephen Eckel, Clinical Associate Professor 
and Associate Director of UNC Hospitals, UNC Eshelman School 
of Pharmacy, seckel@unc.edu; Macary Marciniak, Clinical 
Associate Professor, UNC Eshelman School of Pharmacy, 
macary_marciniak@unc.edu. 
Summary
• In the United Stated (US), the profession of pharmacy 
is pushing for the federal recognition of pharmacists as 
healthcare providers, which would enable payment for 
cognitive and clinical services, such as medication therapy 
management, in medically underserved communities. 
• Most states allow pharmacists to initiate, modify, and 
continue medication regimens through collaborative drug 
therapy management (CDTM) protocols.1 
• In North Carolina, pharmacists with advanced training can 
become credentialed as a clinical pharmacist practitioner (CPP) 
allowing for an expanded level of care including prescriptive 
authority. 
• As the scope of pharmacy practice evolves, more pharmacists 
are pursuing advanced training and board certification 
in a growing number of specialties
Tools, frameworks and support mechanisms
While pharmacists continue to strive for national recognition 
as healthcare providers, some states have passed legislation 
that has expanded the scope of practice for pharmacists 
within that state through collaborative drug therapy 
management (CDTM) protocols and have recognised 
pharmacists as healthcare providers. 
As states continue to develop innovative advanced practice 
models, such as that of the clinical pharmacist practitioner 
(CPP) model in North Carolina, it is the hope of the profession 
that these state frameworks continue to provide support for 
federal recognition of pharmacists as healthcare providers 
along with other recognised professions such as nurse 
practitioners, dentists, optometrists, and psychologists 
among others. 
Certification in defined areas of pharmacy practice has also 
pushed the case for recognition of pharmacists as providers. 
The Board of Pharmacy Specialties (BPS) is the organisation 
that certifies pharmacists in the areas of pharmacotherapy, 
ambulatory care, critical care, nuclear, oncology, paediatrics, 
nutrition support, and psychiatry. Over the past decade there 
has been significant growth in the number of board certified 
pharmacists and the number of specialties pharmacists can be 
certified in. 
To assist with federal recognition, more than 25 national 
pharmacy organisations, companies, and key stakeholders 
united to establish the Patient Access to Pharmacists’ Care 
Coalition (PAPCC) (http://pharmacistscare.org/) which aims 
to expand patient access to pharmacist services in medically 
underserved communities across the country. 
A national grassroots advocacy campaign, Pharmacists 
Provide Care, has also been established which includes an 
informative website with several educational resources about 
provider status (www.pharmacistsprovidecare.com). On this 
website there is a user-friendly tool that allows supporters to 
identify and communicate with his or her elected official to 
urge them to support legislation that recognises pharmacists 
as providers. Supporters can also fill out a provider status 
commitment card to reaffirm their support for being an active 
participant in the campaign for provider status. As of this 
publication, the campaign has nearly 20,000 supporters.
  
Alignment with national strategies 
for healthcare services and delivery
The Patient Protection and Affordable Care Act (ACA) was 
signed into law by President Barack Obama in 2010 with 
the primary goals of improving quality, reducing costs, and 
expanding access to healthcare. As one of the most accessible 
and trusted healthcare professions, pharmacists have the 
opportunity to fulfil the goals of the ACA by providing patient 
care services to a larger population of people, especially 
those living in medically underserved or health professional 
shortage areas. 
As chronic care, access to care, and the provider workforce 
become more important focus areas under the ACA, 
pharmacists are primed to fulfil a variety of needed roles 
as healthcare professionals that provide preventative and 
primary care patient services.2 To help fulfil this role, certified 
pharmacy technicians can allow pharmacists to expand 
patient care services. The federal recognition of pharmacists 
as healthcare providers would further strengthen the goals of 
the ACA of providing high quality, cost-effective patient care 
services that improve patient and health system outcomes. 
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The Community Care of North Carolina (CCNC) is widely 
recognised for its innovative state-wide medical home and 
care management system3. Through a variety of community 
networks, pharmacists in collaboration with other healthcare 
providers are able to manage medication related needs and 
improve health outcomes, thereby strengthening the goals of 
the ACA. Most networks employ at least one pharmacist with 
advanced training as part of a collaborative care model. 
Requirements for CPD/CE
Advanced practice models in certain states such as the CPP 
model in North Carolina require additional practice relevant 
continuing education (CE) hours (35 hours/year) compared to 
that which is required for traditional pharmacists (15 hours/
year). The state of North Carolina allows for the submission 
of a continuing professional development (CPD) portfolio to 
count for licensure and recertification. This is the only state to 
date that allows it.
There is not a specific requirement that CE be associated with 
a university or part of an additional postgraduate training 
programme. However, there are a number of pathways one can 
pursue to obtain the CPP credentials or other specialisations, 
which could include postgraduate training (i.e. residency 
training) associated with a university.
Supporting regulation
The scope of pharmacy practice is regulated at the state level 
by state boards of pharmacy. Most state boards of pharmacy 
have language recognising CDTM, which allows pharmacists to 
initiate, modify and continue drug therapy under a protocol in 
collaboration with other providers for a specific patient 
or patient population. Although the scope of CDTM 
and other patient care services such as immunisations 
differ from state to state, these regulations allow 
pharmacists to further engage with other providers and 
patients in an advanced manner.
Professional recognition 
Certain states in the US have designated titles for advanced 
practice pharmacists with prescriptive authority that have 
met additional training criteria to work alongside physicians 
through collaborative drug therapy management agreements. 
In New Mexico, these pharmacists are called Pharmacist 
clinicians while in Montana and North Carolina they 
are deemed clinical pharmacist practitioners. clinical 
pharmacist practitioners will have “CPP” placed after their 
name as part of their credentials and similarly pharmacist 
clinicians will have “PhC”. 
In 2013, California passed a bill recognising pharmacists as 
providers and established the advanced practice pharmacist 
(APP) designation for pharmacists who meet the additional 
training and certification criteria. Besides advanced practice 
models, pharmacists can be board certified in defined areas 
such as pharmacotherapy which allows them to place board 
certification credentials after their name (i.e. BCPS for Board 
Certified Pharmacotherapy Specialist). Both board certification 
and advanced practice credentials could lead to career 
advancement and professional growth.
While some pharmacists have these advanced designations, 
there is still the challenge for federal government insurers 
and other stakeholders to recognise these titles from a 
reimbursement perspective for the patient care services 
pharmacists provide.1
Ongoing progress
The main push for provider status recognition is through 
the Pharmacists Provide Care Campaign and the Patient 
Access to Pharmacists’ Care Coalition. The priority behind 
these endeavours is to gain legislative support for and pass 
the Pharmacy and Medically Underserved Areas Enhancement 
Act, which will enable Medicare beneficiaries to access 
pharmacists’ services through the amendment of the United 
States Social Security Act.
Lessons learned
What has worked well is that states have recognised the value 
and importance of having pharmacists provide patient care 
services with 48 states having some form of collaborative 
practice between pharmacists and providers.4 Additionally, 
37 states have recognised pharmacists as providers, which 
has further pushed the cause for federal recognition of 
pharmacists as providers.5 However, despite this progress 
and success, much has to be done regarding the regulatory 
framework to support provider status on both the state 
and federal level including reimbursement and payment 
models for pharmacist services.6 The recognition by states 
of pharmacists as providers reduces statutory barriers for 
payment for pharmacist patient care services, but it does not 
necessarily correlate with reimbursement for these services.7
Regarding advanced practice models such as the CPP in North 
Carolina, a survey1 in 2011 indicated that the main challenges 
to implementing an advanced collaborative practice model 
included lack of acceptance by other providers and the 
inability to receive adequate reimbursement for patient 
care services. An additional challenge is there is a lack of 
standardisation regarding CDTM agreements and the scope 
of pharmacy practice they cover since these agreements 
are governed separately by each state.
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Key stakeholders
In the US, professional pharmacy organisations are a driving 
force behind advancing the practice of pharmacy and the 
recognition of pharmacists in advanced roles and as providers. 
Numerous national pharmacy organisations have come 
together to push for recognition of pharmacists as healthcare 
providers under federal law in order to recognise the value 
of and reimburse for the services pharmacists provide 
to patients. In addition, the Patient Access to Pharmacists’ Care 
Coalition has been established which is a multi-stakeholder, 
interdisciplinary initiative to expand patient access 
to pharmacist services in medically underserved areas 
of the country (http://pharmacistscare.org/).
State Boards of Pharmacy and State Pharmacy Associations 
are also a driving force in developing and supporting advanced 
practice models for pharmacists within a particular state. 
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PART 5   
OVERVIEW OF TERMINOLOGY
AND NOMENCLATURE
Global agreement on terminology and definitions is an 
important early step necessary for shared understanding 
of issues around advancing practice and specialisation. 
As a key component of data gathering for this report, FIP 
member organisations, country level contacts from regulatory, 
professional and government agencies and universities, were 
approached to contribute a case study database describing 
aspects of advanced practice and specialisation. 
A template was developed in collaboration with the FIP 
Collaborating Centre, University College London School 
of Pharmacy, Faculty of Pharmacy and Pharmaceutical 
Sciences at Monash University, and FIP Education Initiative. 
The template was validated by an expert working group, 
drawn from a cross-section of FIP sections and special-interest 
groups. Data was collected between January 2015 
and May 2015. 
Cases were edited and returned to original authors for 
approval. Details of individual cases are in Part 4 of this report. 
The data collection template and report are available 
for download from www.fip.org/educationreports. 
Collation of input from 18 case studies (covering 17 countries) 
indicates significant differences in our understanding and 
usage of common terms. For this report no attempt has been 
made to harmonise these definitions, or to suggest global 
definitions; however FIPEd will continue to investigate 
how to contribute to improved common understanding of 
terminology in this area, and work towards a transnational 
understanding of specialisation and advanced practice.
Presented in the tables are the responses received when 
contributors were asked to share their definitions of the 
following common terms.
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WHO regional 
country examples
EUROPE
EUROPE
WESTERN PACIFIC
SOUTH-EAST ASIA
WESTERN PACIFIC
WESTERN PACIFIC
WESTERN PACIFIC
EUROPE
AMERICAS
AMERICAS
AMERICAS
AMERICAS
PHARMINE
Examples of definitions of “Specialisation”
Pharmacists are considered qualified for a specialisation if, after concluding their university diploma, have undergone the 
PPS Specialists’ Programme on one of the areas of specialisation and achieve the title of ‘specialist’.
Specialist – someone fulfilling the role and with specialist knowledge as defined by Expert Practice Curricula produced 
by specialist groups in pharmacy.
A recognised branch of a profession in which one specialises.
The specialisation in pharmacy education is at postgraduate level. At present ‘The Master of Pharmacy (M.Pharm) Course 
Regulations, 2014’ is in vogue prescribing the following specialisations (e.g.): 1. Pharmaceutics ; 2.  Industrial Pharmacy ; 
3. Pharmaceutical Technology ; 4. Pharmaceutical Chemistry ; 5. Pharmaceutical Analysis.
The speciality practice is governed by specialisation held by the pharmacist. For example the M.Pharm of following 
specialisations predominantly practice in research, manufacturing, analysis, quality control, etc. - a. Pharmaceutics, 
b. Industrial Pharmacy, c. Pharmaceutical Technology, d. Pharmaceutical Chemistry, e. Pharmaceutical Analysis, 
f. Pharmaceutical Quality Assurance, g. Pharmaceutical Biotechnology. 2.Similarly holders of M.Pharm. regulatory affairs 
practice in the government sector (drug regulatory departments, departments regulating education like PCI, State Pharmacy 
Councils etc.). 3.Holders of M.Pharm. pharmacy practice basically practice in community pharmacy and hospital pharmacy.
There are two meanings: hospital pharmacist or community pharmacist; pharmacists who have specialised skills in more 
specific area.
Term used mainly in hospital practice to recognise advanced skills and knowledge in a specified specialised area of practice 
e.g. renal pharmacist, medicines information.
Refers to advanced practice in a particular clinical area/discipline. The PSAB recognises the following pharmacy specialties 
for a start: 1. Advanced Pharmacotherapy which includes: cardiology pharmacy, geriatric pharmacy, infectious diseases 
pharmacy and psychiatric pharmacy; 2. Oncology Pharmacy.
Specialised training in the Health Sciences is an official, structured program whose purpose is to provide professionals with 
the knowledge, techniques, skills and aptitudes needed for the relevant specialty, while at the same time having the 
candidate gradually take over the responsibilities inherent to the practice of the specialty.
An identifiable and distinct field of practice that calls for special knowledge and skills acquired by education and training 
and/or experience beyond the basic pharmaceutical education and training. Specialisation may focus on a certain 
therapeutic area (e.g. – oncology) or an area of practice, e.g. health system administration.
“An identifiable field of pharmacy practice that requires specialised functioning and is distinct from other BPS-recognised 
pharmacy specialties” .
Specialisation often refers to pharmacists who are board certified in the areas of ambulatory care, critical care, nutrition 
support, nuclear, oncology, paediatric, pharmacotherapy, and psychiatry. Specialisation can also refer to the concept of 
pharmacists pursuing postgraduate training or experience within a defined pharmacy practice area such as cardiology, 
oncology, infectious disease, solid organ transplant, critical care, paediatrics, etc. which often precedes formal board 
certification. See article “Growing trend of specialisation, board certification”
For the purpose of the needs assessment of pharmacist specialisation, the following definitions were used: Pharmacist 
Specialists: maintain an active clinical practice that is limited to a particular type of patients (e.g. geriatrics, ambulatory 
care). Specialties can be either broad (e.g. Pharmacotherapy specialists) or focused (e.g. oncology or cardiology specialists). 
Pharmacy specialisation requires an advanced body of knowledge distinct of the general practitioner and a specialised or 
enhanced depth of competency including knowledge, skills, attitudes and accountabilities based on the physical, social, 
and health sciences, sufficient to manage the most complex of cases and provide clinical leadership in the field. Generally, 
specialty competencies attained through formal learning /education programs and practice in the field are recognised 
through a certification process.
Specialty practice (specialism) is the training on a specific topic as part of a profession or field of application for various 
professions, such capacitation gets through by an intensive theoretical and practical training
Specialisation has a syntax meaning of becoming an expert in one particular skill or area. It is not universally accepted 
as a term to denote ‘sector of practice’. (…) “means an advanced understanding of a specific sector (hospital pharmacy) 
while “specialist practice” means specific competence in a defined field of practice (for example, oncology pharmacy 
or radiopharmacy).” 
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WHO regional 
country examples
WESTERN PACIFIC
EUROPE
SOUTH-EAST ASIA
Examples of definitions of “Defined area of practice”
The pharmacist’s area of responsibility and accountability in professional practice. As defined in the Advanced Pharmacy 
Practice Framework (APPF). Preferred terms are Area of expert professional practice; Scope of practice.
The specific area of responsibility in a role, which may be a specialist or general area of practice but would be covered in 
depth beyond that of a core area as is the focus of that role. Knowledge and skills are defined in the generic and specialist 
‘Professional curricula’. 
Various areas of expert professional practice are defined as under – ‘Community Pharmacist’ means an individual currently 
registered and who works according to legal and ethical guidelines to ensure the correct and safe supply of medical 
products to the general public. They are involved in maintaining and improving people's health by providing advice and 
information as well as supplying prescription medicines. ‘Hospital Pharmacist’ means an individual currently registered and 
who works in a hospital pharmacy service, primarily within the public/private sector. They are responsible for ensuring the 
safe, appropriate and cost-effective use of medicines. Hospital pharmacists use their specialist knowledge to dispense drugs 
and advise patients about the medicines, which have been prescribed. They work collaboratively with other healthcare 
professionals to devise the most appropriate drug treatment for patients. 
Some pharmacists are also involved in manufacturing required drug treatments. ‘Drug Information Pharmacist’ means 
an individual currently registered who works in a community pharmacy/hospital pharmacy/teaching hospital/ other 
healthcare settings and provides information and advice regarding drug interactions, side effects, dosage and proper 
medication storage to patients/physicians/dentists/other health care professionals. ‘Clinical Pharmacist’ means an 
individual currently registered and who provides patient care that optimises the use of medication and promotes health, 
wellness and disease prevention. Clinical pharmacists care for patients in all health care settings. Clinical pharmacists often 
collaborate with physicians and other healthcare professionals.
WHO regional 
country examples
WESTERN PACIFIC
WESTERN PACIFIC
AMERICAS
EUROPE
AMERICAS
AMERICAS
EUROPE
Examples of definitions of “Advanced Practice”
Practice that is so significantly different from that achieved at initial registration that it warrants recognition by 
professional peers and the public of the expertise of the practitioner and the education, training and experience from which 
that capability was derived.
Practice necessary of advanced clinical and pharmaceutical knowledge, skills, and experiences.
Advanced Practice Pharmacists are recognised in California’s state law as pharmacists who may practice pharmacy 
at an advanced scope.
‘Advanced Training’: Masters programs are designed to give students advanced training of a specialised or multi-disciplinary 
nature, geared toward an academic or professional specialisation, or to initiate them in research activities.
Advanced practice often refers to innovative practice models such as the Clinical Pharmacist Practitioner (CPP) model 
in North Carolina and the Pharmacist Clinician (PhC) model in New Mexico. Advanced practice settings, pharmacists are 
involved with provision of more expanded direct patient care through comprehensive disease management, CDTM, 
medication management, health promotion/disease prevention, care coordination and follow‐up patient care. Many 
of these services are similar in scope and complexity to other primary care services delivered in our healthcare system.
Defining an Advanced Practice Pharmacist: graduation from an accredited experiential pharmacy training program such 
as a residency, clinical Masters program, or Doctor of Pharmacy program; ability to collaborate with the healthcare team in 
their clinical practice; ability to access and interpret comprehensive health information relevant to the patient’s care; ability 
to assess and monitor a patient’s signs, symptoms, and response to therapy; expectation to practice within the person’s 
scope of expertise; recognition of duty to incorporate evidence-based decisions and the patient’s goals and preferences into 
the care plan; recognition of duty to communicate interventions and plans to the rest of the care team; ability to monitor 
the outcomes of interventions; accountability to ensure appropriate follow-up; and responsibility for the patient’s care.
Pharmacy professionals who are experienced practitioners; who are developing complex skills; or who are recognised at 
NHS Consultant or higher levels of practice. For example, registered practitioners are very often involved in work relating to 
patients, customers and other staff and are the ones who are experiencing how day-to-day healthcare works in action. They 
often undertake more education, training and professional development opportunities to further consolidate and develop 
their skills and knowledge in everyday practice. They are uniquely placed to develop experience across all six clusters. 
This experience will, of course vary from sector to sector, but these experiences can be mapped to very generic 
competencies with some additional support and guidance. Essentially the framework is very useful for capturing a 
practitioner’s experience and development as evidence of advancement. More experienced practitioners hold more complex 
roles and have greater responsibility for outcomes and deliverables. They develop their abilities though delivery of services, 
higher levels of responsibility and accountability, by working with colleagues in other settings and projects and by working 
across boundaries, disciplines and sectors. Familiarity with a specific focus of practice will enable them to improve 
healthcare for patients, to innovate, educate and research their practice, whatever their sector. As established members of 
staff, area teams, company or Trust directors or as pharmacy owners and partners, they are able to develop their leadership 
abilities by actively contributing to the running of the organisation and to the way care is provided in complex systems.
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EUROPE
WESTERN PACIFIC
WESTERN PACIFIC
AMERICAS
AMERICAS
AMERICAS
WESTERN PACIFIC
Examples of definitions of “Scope of Practice”
Defined as Core Areas of Practice: Core areas cover the common areas that any practitioner would be expected to be familiar 
with in a similar role at an advanced level. 
The core areas of pharmacy practice include leadership, management, education, training and development, and research 
and evaluation. 
Core clinical areas are defined in the generic and specialist, professional curricula.
The boundaries within which a health professional may practice.
A time sensitive, dynamic aspect of practice, which indicates those professional activities that a pharmacist is educated, 
competent and authorised to perform and for which they are accountable. 
Describes the procedures, actions, and processes that a healthcare practitioner is permitted to undertake in keeping with 
the terms of their professional license.
Types of service the practitioner is trained and permitted to do within their own organisation/province. Scope of practice 
varies.
“The boundaries within which a health professional may practice. For pharmacists, the scope of practice is generally 
established by the board or agency that regulates the profession in a given state or organisation.” The article “Scope of 
contemporary pharmacy practice: Roles, responsibilities and functions of pharmacists and pharmacy technicians” provides 
an overview of the current context and scope of pharmacy practice and has a great appendix with a terminology glossary. 
Please also note that ‘scope of practice’ is governed at the state level by state boards of pharmacy.
The scopes of practice describe the health services that form part of the profession of pharmacy. There are three scopes of 
practice - intern pharmacist, pharmacist, and pharmacist prescriber. All advanced services fall within the Pharmacist Scope 
of Practice except prescribing which has its own scope.
WHO regional 
country examples
WESTERN PACIFIC
EUROPE
Examples of definitions of “Expert professional practice”
A particular field or subject in, which an individual has acquired the knowledge, skills and experiences for them to be 
accepted as an expert.
The specific area of responsibility in a role, which may be a specialist or general area of practice but would be covered in 
depth beyond that of a core area as is the focus of that role. Knowledge and skills are defined in the generic and specialist 
‘Professional curricula’. 
A defined area may be: an area of clinical practices e.g. cardiology, paediatrics a specific role e.g. Area Manager, 
Superintendant Pharmacist a service area e.g. manufacturing of cytotoxics, medicines information.
WHO regional 
country examples
AMERICAS
WESTERN PACIFIC
WESTERN PACIFIC
WESTERN PACIFIC
SOUTH-EAST ASIA
Examples of definitions of “Privileging”
The process that healthcare organisations employ to authorise practitioners to provide specific services to their patients. 
Also sometimes termed “credentialing”, this is a quality assured process, which recognises a practitioner’s attainment of the 
required knowledge and skills at a particular level of practice. Crucially, this is a process conducted through professional 
peer review, and is not connected with a regulatory function. It exists for the purposes of validation of practice by peers, and 
demonstrates a recognition of practice that has value and merit for the general public and other members of the profession 
or professional colleagues. 
The process by which a healthcare organisation, having reviewed an individual healthcare provider’s credentials and 
performance and found them satisfactory, authorises that person to perform a specific scope of patient care services within 
that organisation.
The process that healthcare organisations employ to authorise practitioners to provide specific services to their patients.
Permission grated by a facility or institute to the individual to allow them to undertake specific procedures or services. 
Not specialised in pharmacy.
The healthcare organisations like hospitals, dispensaries or community pharmacies and other appointing authorities after 
being satisfied of the credentials and performance of pharmacist, allow the pharmacist to perform his/her duties.
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WESTERN PACIFIC
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EUROPE
Examples of definitions of “Extended Practice”
An extension of existing scope of practice, requiring additional education and training and demonstration of competence. 
Bachelor of Pharmacy (B.Pharm.) is a four years course in which there is a provision for lateral entry for pharmacist holding 
diploma in pharmacy qualification for admission to direct 2nd year B.Pharm. course. Similarly there is a provision of lateral 
entry in Pharm.D. course for pharmacist holding B.Pharm. qualification to take direct admission in IVth year Pharm.D. course 
which is six years duration. Since above provisions are available in the statutory regulations, it motivates the pharmacist to 
go for extended practice requiring additional education and training for which the scope is available in the Pharmacy 
Practice Regulations, 2015.
Pharmacist Extended Practice Regulations made under Section 83 of the Pharmacy Act - “extended practice” means any of 
the following practices: (i) directly administering drug therapy to a patient, including drug therapy by injection, (ii) testing.
Pharmacist and Pharmacy Technician Profession Regulations made under the Regulated Health Professions Act 2014 - 
extended practice by a pharmacist includes any of the following activities: (a) administering a vaccine or drug therapy 
to a patient (i) by intradermal, subcutaneous or intramuscular injection, (ii) orally, including sublingual and buccal 
administration, (iii) topically, including ophthalmic, otic and intranasal administration, and (iv) by inhalation; (b) on and after 
1st April, 2016, dispensing methadone and suboxone; (c) prescribing drugs for minor ailments as authorised in the Practice 
of Pharmacist and Pharmacy Technicians Regulations. 
Pharmaceutical Regulation made under The Pharmaceutical Act  - "extended practice pharmacist" means a member whose 
name is entered on the register of extended practice pharmacists under Part 12. To be an applicant for extended practice 
pharmacist: 95(1) An applicant for registration as an extended practice pharmacist must (a) be a member who is qualified 
as a specialist in an area described in section 96; (b) submit an application to the board in the form approved by the council; 
(c) practice or undertake to practice in a collaborative practice that meets the requirements of clause(5) (c); and (d) pay the 
fee provided for in the by-laws. Section 96 - A member is qualified as a specialist in an area upon providing evidence 
satisfactory to the registrar that he or she has one or more of the following qualifications: (a) board certification from 
the American Board of Pharmacy Specialties in one of the following specialties, is currently practising, and has practised 
for at least 1000 hours in the two years before applying for registration, in a healthcare setting in one of the following 
specialty areas: (i) ambulatory care pharmacy, (ii) nuclear pharmacy, (iii) nutrition support pharmacy.
Pharmacists must undertake accredited training in order to provide flu vaccination service. This is not officially referred 
to as extended practice, but is provided for by legislation (http://www.irishstatutebook.ie/2011/en/si/0525.html).
WHO regional 
country examples
EUROPE
SOUTH-EAST ASIA
EUROPE
WESTERN PACIFIC
Examples of definitions of “Professional Recognition”
Professional recognition comes as a title awarded by the PPS that might be relevant for the pursuit of specialised 
pharmaceutical acts. Title awarded by the PPS can come from special academic education (MSc, PhD, etc.), other relevant 
education or specialisation programmes of the PPS. These are specially detailed in the PPS database and come written on 
the pharmacists’ professional card. Some professional acts are reserved for specialisation titles awarded by the PPS.
The term used for professional recognition is “Registered Pharmacist”, as an acknowledgement of a pharmacist’s 
professional status and right to practice the pharmacy profession in accordance with prescribed professional standards.
Public, express and individual recognition of the level attained by a healthcare professional in terms of knowledge, 
experience in service, teaching and research activities, as well as of complying with the service or research-oriented goals
 of the organisation where they provide their services. Access to the professional development system is voluntary and 
open to any professional who provides services within Spain. 
The recognition is divided into four levels. Obtaining the first level and accessing subsequent levels requires a favourable 
evaluation of the applicant’s knowledge, skill, accredited continuing training, and teaching and research activity. 
Also considered will be the results of hospital care services, their quality, and compliance with assessment indicators. 
Anyone with five years of accredited professional practice is eligible for the first level.
Advanced and Extended Pharmacy Practice - an environmental snapshot discusses professional recognition for advanced 
practice for pharmacy and other professions. There is no generally defined term used in practice to describe aspects of 
advancing practice and specialisation. The professional recognition of advanced practice will be via the awarding of the 
Credential of Advanced Practice Pharmacist.
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WHO regional 
country examples
WESTERN PACIFIC
AMERICAS
EUROPE
WESTERN PACIFIC
SOUTH-EAST ASIA
AMERICAS
AMERICAS
AMERICAS
WESTERN PACIFIC
WESTERN PACIFIC
Examples of definitions of “Credential” or “Credentialing”
Credential: Documented evidence of professional qualifications. Credentialing: Process by which an authorised 
organisation/body reviews and verifies a practitioner’s qualifications, skills, experience and competencies against defined 
standards, applying for advanced practice recognition by submitting a practice portfolio for evaluation against the APPF 
and the standards/policies and procedures.
The CSHP permits its fellows to use the credential FCSHP and for those that complete a residency program may use ACPR.
 
A process of acts as a workforce incentive to develop a broad scope of advanced competencies necessary for service 
delivery and patient care. This forms part of professional recognition, a key element of which is a system for awarding 
credentials following quality assured assessments for practice beyond day one.
Authorising a defined practice activity. Just starting to use this term, as it is used widely internationally and better reflects 
the situation rather than the current common term of ‘accreditation’.
“Credentialing” is a process that identifies when a defined set of knowledge, skills and experiences has been met at a 
defined standard of practice, and where an individual is able to demonstrate this against a consistent method of 
assessment.
“A credential is a documented evidence of professional qualifications”. “Credentialing” refers to one of two processes: the 
first is the process of granting a credential (such as granting a practitioner a license to practice or granting board 
certification); the second is the process by which an organisation or institution obtains, verifies, and assesses an individuals’ 
qualifications to provide patient care services.
“Credentialing” (1) the process of granting a credential (a designation that indicates qualifications in a subject or an area); 
and (2) the process by which an organisation or institution obtains, verifies, and assesses an individual’s qualifications to 
provide patient care services. “Credential”: documented evidence of professional qualifications. Academic degrees, state 
licensure, residency certificates, and certification are all examples of credentials. Credentialing is frequently done at an 
institutional level (e.g. – a health system will credential its own staff).
“Tuition” is the credential that certifies that the holder is a registered professional by the correspondent authority.
Credentialing is required for specialist pharmacists. The credential is offered by PSAB/SPC. 
Credential is usually given to individuals (for programmes, accreditation is often granted).; a document presenting 
the evidence of successful results of certain training.
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The data presented in this report represents the first time 
that specialisation and advanced practice, as defined scopes 
of practice, have been codified and examined. FIP Education 
Initiative will continue to move forward in this area with the 
aim of providing a foundation for workforce development 
in a transnational context. It should be noted that the 
foundations of practice, and early career development are 
considered by FIPEd to be of equal, if not greater, importance 
with regards to workforce development, but we also recognise 
that many in the pharmacy workforce are at a practice level 
beyond that of foundation.
What is clear from this first collection of global data 
is that professional advancement and the professional 
recognition of advancement in practice is a developing trend 
worldwide. This can be attributed to a number of reasons, 
such as the increasingly complex role of pharmacists, the 
enhancement of more patient facing roles and greater extent 
of clinical pharmacy with the associated risk this entails 
and a consequent need to be able to endorse professional 
capabilities. Comparisons and parallels with medical practice 
and the advancement of physicians, for example, are notable. 
As pharmacists continue to become more clinically-oriented 
health professionals, with enhanced responsibilities 
and accountabilities for pharmaceutical care in clinical 
environments, then clear pathways for workforce 
development, coupled with professional recognition and 
credentialing of practitioners, is an important consideration. 
In addition, this represents a clear opportunity for 
transnational collaboration and further opportunities 
for transnational recognition of advanced capabilities 
for the pharmacy workforce.
The public and our patients should expect the highest 
possible pharmaceutical care from professional practitioners 
worldwide, without exception. A clear demonstration and 
assurance of competence and capability that is commensurate 
with advanced and expert practice is a clear message to civil 
society that pharmacists possess this expertise; professional 
recognition, credentialing and quality assured specialisation 
are part of this demonstration of competence and capability. 
It is in the interest of patients, health systems and our 
profession that we develop a common and shared 
understanding of what we mean by “specialisation” 
and by “advanced practice”. This is a key driver for future 
workforce development.  
PART 6   
SUMMARY AND CONCLUSIONS
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